Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Multiple Sclerosis

  Free Subscription


Articles published in Mult Scler

Retrieve available abstracts of 587 articles:
HTML format
Text format



Single Articles


    May 2018
  1. FROEHLICH A, Schmidt S, Landsberg J, Bieber T, et al
    Spontaneous regression of tumor-stage cutaneous T-cell lymphoma in a multiple sclerosis patient after discontinuing fingolimod.
    Mult Scler. 2018 May 1:1352458518774444. doi: 10.1177/1352458518774444.
    PubMed     Text format    


  2. NAUTA IM, Balk LJ, Sonder JM, Hulst HE, et al
    The clinical value of the patient-reported multiple sclerosis neuropsychological screening questionnaire.
    Mult Scler. 2018 May 1:1352458518777295. doi: 10.1177/1352458518777295.
    PubMed     Text format     Abstract available


  3. ROMME CHRISTENSEN J, Komori M, von Essen MR, Ratzer R, et al
    CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage.
    Mult Scler. 2018 May 1:1352458518774880. doi: 10.1177/1352458518774880.
    PubMed     Text format     Abstract available


  4. MILLS EA, Mao-Draayer Y
    Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients.
    Mult Scler. 2018 May 1:1352458518775550. doi: 10.1177/1352458518775550.
    PubMed     Text format     Abstract available


  5. VAN DER VUURST DE VRIES RM, Wong YYM, Mescheriakova JY, van Pelt ED, et al
    High neurofilament levels are associated with clinically definite multiple sclerosis in children and adults with clinically isolated syndrome.
    Mult Scler. 2018 May 1:1352458518775303. doi: 10.1177/1352458518775303.
    PubMed     Text format     Abstract available


  6. SCHEE JP, Viswanathan S
    Pure spinal multiple sclerosis: A possible novel entity within the multiple sclerosis disease spectrum.
    Mult Scler. 2018 May 1:1352458518775912. doi: 10.1177/1352458518775912.
    PubMed     Text format     Abstract available


  7. BOESEN MS, Koch-Henriksen N, Thygesen LC, Eriksson F, et al
    Infections seem to be more frequent before onset of pediatric multiple sclerosis: A Danish nationwide nested case-control study.
    Mult Scler. 2018 May 1:1352458518771871. doi: 10.1177/1352458518771871.
    PubMed     Text format     Abstract available


  8. BAKER G, Nair KPS, Baster K, Rosato R, et al
    Reliability and acceptability of the Multiple Sclerosis Quality of Life-29 questionnaire in an English-speaking cohort.
    Mult Scler. 2018 May 1:1352458518776583. doi: 10.1177/1352458518776583.
    PubMed     Text format     Abstract available


  9. BEESLEY R, Anderson V, Harding KE, Joseph F, et al
    Impact of the 2017 revisions to McDonald criteria on the diagnosis of multiple sclerosis.
    Mult Scler. 2018 May 1:1352458518778007. doi: 10.1177/1352458518778007.
    PubMed     Text format    


  10. HUGOS CL, Cameron MH, Chen Z, Chen Y, et al
    A multicenter randomized controlled trial of two group education programs for fatigue in multiple sclerosis: Long-term (12-month) follow-up at one site.
    Mult Scler. 2018 May 1:1352458518775920. doi: 10.1177/1352458518775920.
    PubMed     Text format     Abstract available


    April 2018
  11. ALMEIDA KJ, Barreto-Soares RV, Campos-Sousa RN, Campos-Sousa MG, et al
    Pulmonary paracoccidioidomycosis associated with the use of natalizumab in multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518763091. doi: 10.1177/1352458518763091.
    PubMed     Text format     Abstract available


  12. MCNICHOLAS N, Lockhart A, Yap SM, O'Connell K, et al
    New versus old: Implications of evolving diagnostic criteria for relapsing-remitting multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518770088. doi: 10.1177/1352458518770088.
    PubMed     Text format     Abstract available


  13. KREMER D, Kury P, Hartung HP
    ECTRIMS/ACTRIMS 2017: Closing in on neurorepair in progressive multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518768770. doi: 10.1177/1352458518768770.
    PubMed     Text format     Abstract available


  14. KOBELT G, Langdon D, Jonsson L
    The effect of self-assessed fatigue and subjective cognitive impairment on work capacity: The case of multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518769837. doi: 10.1177/1352458518769837.
    PubMed     Text format     Abstract available


  15. VAVASOUR IM, Tam R, Li DK, Laule C, et al
    A 24-month advanced magnetic resonance imaging study of multiple sclerosis patients treated with alemtuzumab.
    Mult Scler. 2018 Apr 1:1352458518770085. doi: 10.1177/1352458518770085.
    PubMed     Text format     Abstract available


  16. MARRIE RA, Montalban X
    Disease-modifying therapy in multiple sclerosis: Two guidelines (almost) passing in the night.
    Mult Scler. 2018;24:558-562.
    PubMed     Text format    


  17. LORSCHEIDER J, Benkert P, Lienert C, Hanni P, et al
    Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518768433. doi: 10.1177/1352458518768433.
    PubMed     Text format     Abstract available


  18. SAUL A, Taylor B, Simpson S Jr, Ponsonby AL, et al
    Polymorphism in the serotonin transporter gene polymorphisms ( 5-HTTLPR) modifies the association between significant life events and depression in people with multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518770021. doi: 10.1177/1352458518770021.
    PubMed     Text format     Abstract available


  19. LLUFRIU S, Rocca MA, Pagani E, Riccitelli GC, et al
    Hippocampal-related memory network in multiple sclerosis: A structural connectivity analysis.
    Mult Scler. 2018 Apr 1:1352458518771838. doi: 10.1177/1352458518771838.
    PubMed     Text format     Abstract available


  20. CREARY LE, Mallempati KC, Gangavarapu S, Caillier SJ, et al
    Deconstruction of HLA-DRB1*04:01:01 and HLA-DRB1*15:01:01 class II haplotypes using next-generation sequencing in European-Americans with multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518770019. doi: 10.1177/1352458518770019.
    PubMed     Text format     Abstract available


  21. MCCLURG D, Bugge C, Elders A, Irshad T, et al
    Factors affecting continuation of clean intermittent catheterisation in people with multiple sclerosis: Results of the COSMOS mixed-methods study.
    Mult Scler. 2018 Apr 1:1352458518768722. doi: 10.1177/1352458518768722.
    PubMed     Text format     Abstract available


  22. WAGLEY S, Bokori-Brown M, Morcrette H, Malaspina A, et al
    Evidence of Clostridium perfringens epsilon toxin associated with multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518767327. doi: 10.1177/1352458518767327.
    PubMed     Text format     Abstract available


  23. GIOVANNONI G, Soelberg Sorensen P, Cook S, Rammohan KW, et al
    Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.
    Mult Scler. 2018 Apr 1:1352458518771875. doi: 10.1177/1352458518771875.
    PubMed     Text format     Abstract available


  24. GIORDANA MT, Cavalla P, Uccelli A, Laroni A, et al
    Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuation.
    Mult Scler. 2018 Apr 1:1352458518763095. doi: 10.1177/1352458518763095.
    PubMed     Text format     Abstract available


  25. GIACOMINI PS
    Rebound disease in multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518772913. doi: 10.1177/1352458518772913.
    PubMed     Text format    


  26. HARMEL P, Schlunk F, Harms L
    Fulminant rebound of relapsing-remitting multiple sclerosis after discontinuation of dimethyl fumarate: A case report.
    Mult Scler. 2018 Apr 1:1352458517741191. doi: 10.1177/1352458517741191.
    PubMed     Text format     Abstract available


    March 2018
  27. KOENIG KA, Rao SM, Lowe MJ, Lin J, et al
    The role of the thalamus and hippocampus in episodic memory performance in patients with multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518760716. doi: 10.1177/1352458518760716.
    PubMed     Text format     Abstract available


  28. GOBEL K, Ruck T, Meuth SG
    Cytokine signaling in multiple sclerosis: Lost in translation.
    Mult Scler. 2018 Mar 1:1352458518763094. doi: 10.1177/1352458518763094.
    PubMed     Text format     Abstract available


  29. LEE JY, De Jager PL
    What is the epigenome and is it involved in multiple sclerosis?
    Mult Scler. 2018;24:268-269.
    PubMed     Text format    


  30. SILLER N, Kuhle J, Muthuraman M, Barro C, et al
    Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518765666. doi: 10.1177/1352458518765666.
    PubMed     Text format     Abstract available


  31. SOWA P, Harbo HF, White NS, Celius EG, et al
    Restriction spectrum imaging of white matter and its relation to neurological disability in multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518765671. doi: 10.1177/1352458518765671.
    PubMed     Text format     Abstract available


  32. CORTI L, Ayrignac X, Carra Dalliere C, Charif M, et al
    Late activity rebound in non-active multiple sclerosis: A rare event.
    Mult Scler. 2018 Mar 1:1352458518765670. doi: 10.1177/1352458518765670.
    PubMed     Text format    


  33. CASTELLI L, Prosperini L, Pozzilli C
    Balance worsening associated with nabiximols in multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518765649. doi: 10.1177/1352458518765649.
    PubMed     Text format     Abstract available


  34. GRAETZ C, Groger A, Luessi F, Salmen A, et al
    Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518763541. doi: 10.1177/1352458518763541.
    PubMed     Text format     Abstract available


  35. HUA LH, Fan TH, Conway D, Thompson N, et al
    Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60.
    Mult Scler. 2018 Mar 1:1352458518765656. doi: 10.1177/1352458518765656.
    PubMed     Text format     Abstract available


  36. LANZILLO R, Moccia M, Criscuolo C, Cennamo G, et al
    Optical coherence tomography angiography detects retinal vascular alterations in different phases of multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518768060. doi: 10.1177/1352458518768060.
    PubMed     Text format    


  37. VAN GEEST Q, Boeschoten RE, Keijzer MJ, Steenwijk MD, et al
    Fronto-limbic disconnection in patients with multiple sclerosis and depression.
    Mult Scler. 2018 Mar 1:1352458518767051. doi: 10.1177/1352458518767051.
    PubMed     Text format     Abstract available


  38. TOLEDANO M, Weinshenker BG, Kaufmann TJ, Parisi JE, et al
    Demographics and clinical characteristics of episodic hypothermia in multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518767045. doi: 10.1177/1352458518767045.
    PubMed     Text format     Abstract available


  39. LEIBOVITCH EC, Lin CM, Billioux BJ, Graves J, et al
    Prevalence of salivary human herpesviruses in pediatric multiple sclerosis cases and controls.
    Mult Scler. 2018 Mar 1:1352458518765654. doi: 10.1177/1352458518765654.
    PubMed     Text format     Abstract available


    February 2018
  40. JAEGER S, Paul F, Scheel M, Brandt A, et al
    Multiple sclerosis-related fatigue: Altered resting-state functional connectivity of the ventral striatum and dorsolateral prefrontal cortex.
    Mult Scler. 2018 Feb 1:1352458518758911. doi: 10.1177/1352458518758911.
    PubMed     Text format     Abstract available


  41. DE STEFANO N, Giorgio A, Tintore M, Pia Amato M, et al
    Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations.
    Mult Scler. 2018;24:214-221.
    PubMed     Text format    


  42. ROOSTAEI T, Sadaghiani S, Mashhadi R, Falahatian M, et al
    Convergent effects of a functional C3 variant on brain atrophy, demyelination, and cognitive impairment in multiple sclerosis.
    Mult Scler. 2018 Feb 1:1352458518760715. doi: 10.1177/1352458518760715.
    PubMed     Text format     Abstract available


  43. CAVALERA C, Rovaris M, Mendozzi L, Pugnetti L, et al
    Online meditation training for people with multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2018 Feb 1:1352458518761187. doi: 10.1177/1352458518761187.
    PubMed     Text format     Abstract available


  44. CAMARA-LEMARROY CR, Castillo J, Sastre-Garriga J, Tintore M, et al
    Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis: A case report.
    Mult Scler. 2018 Feb 1:1352458518761185. doi: 10.1177/1352458518761185.
    PubMed     Text format     Abstract available


  45. PIEHL F, Hillert J
    Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - Yes.
    Mult Scler. 2018 Feb 1:1352458518757930. doi: 10.1177/1352458518757930.
    PubMed     Text format    


  46. CREE BA
    Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - Commentary.
    Mult Scler. 2018 Feb 1:1352458518760717. doi: 10.1177/1352458518760717.
    PubMed     Text format    


  47. WALLIN MT
    Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - No.
    Mult Scler. 2018 Feb 1:1352458518757931. doi: 10.1177/1352458518757931.
    PubMed     Text format    


    January 2018
  48. HILVEN K, Vandebergh M, Smets I, Mallants K, et al
    Genetic basis for relapse rate in multiple sclerosis: Association with LRP2 genetic variation.
    Mult Scler. 2018 Jan 1:1352458517749894. doi: 10.1177/1352458517749894.
    PubMed     Text format     Abstract available


  49. FEUCHT N, Maier M, Lepennetier G, Pettenkofer M, et al
    Optical coherence tomography angiography indicates associations of the retinal vascular network and disease activity in multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458517750009. doi: 10.1177/1352458517750009.
    PubMed     Text format     Abstract available


  50. DI STADIO A, Ralli M
    Inner ear involvement in multiple sclerosis: An underestimated condition?
    Mult Scler. 2018 Jan 1:1352458518750010. doi: 10.1177/1352458518750010.
    PubMed     Text format    


  51. DAMOTTE V, Lizee A, Tremblay M, Agrawal A, et al
    Harnessing electronic medical records to advance research on multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458517747407. doi: 10.1177/1352458517747407.
    PubMed     Text format     Abstract available


  52. DE STEFANO N, Giorgio A
    Response to 'Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis?' by Schiffmann et al.
    Mult Scler. 2018 Jan 1:1352458517748476. doi: 10.1177/1352458517748476.
    PubMed     Text format    


  53. SCHIFFMANN I, Scheiderbauer J, Riemann-Lorenz K, Heesen C, et al
    Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis?
    Mult Scler. 2018 Jan 1:1352458517749895. doi: 10.1177/1352458517749895.
    PubMed     Text format    


  54. SEGAL BM, Cohen JA, Antel J
    Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2017: Environmental factors, genetics, and epigenetics in MS susceptibility and clinical course.
    Mult Scler. 2018;24:4-5.
    PubMed     Text format     Abstract available


  55. TREMLETT H, Waubant E
    Gut microbiome and pediatric multiple sclerosis.
    Mult Scler. 2018;24:64-68.
    PubMed     Text format     Abstract available


  56. CASTRO K, Casaccia P
    Epigenetic modifications in brain and immune cells of multiple sclerosis patients.
    Mult Scler. 2018;24:69-74.
    PubMed     Text format     Abstract available


  57. TANKOU SK, Regev K, Healy BC, Cox LM, et al
    Investigation of probiotics in multiple sclerosis.
    Mult Scler. 2018;24:58-63.
    PubMed     Text format     Abstract available


  58. VOSKUHL RR, Sawalha AH, Itoh Y
    Sex chromosome contributions to sex differences in multiple sclerosis susceptibility and progression.
    Mult Scler. 2018;24:22-31.
    PubMed     Text format     Abstract available


  59. HAASE S, Haghikia A, Gold R, Linker RA, et al
    Dietary fatty acids and susceptibility to multiple sclerosis.
    Mult Scler. 2018;24:12-16.
    PubMed     Text format     Abstract available


  60. HARROUD A, Richards JB
    Mendelian randomization in multiple sclerosis: A causal role for vitamin D and obesity?
    Mult Scler. 2018;24:80-85.
    PubMed     Text format     Abstract available


  61. DOLEI A
    The aliens inside us: HERV-W endogenous retroviruses and multiple sclerosis.
    Mult Scler. 2018;24:42-47.
    PubMed     Text format     Abstract available


  62. CANTO E, Oksenberg JR
    Multiple sclerosis genetics.
    Mult Scler. 2018;24:75-79.
    PubMed     Text format     Abstract available


  63. WAUBANT E
    Effect of puberty on multiple sclerosis risk and course.
    Mult Scler. 2018;24:32-35.
    PubMed     Text format     Abstract available


  64. HODEL J, Bapst B, Outteryck O, Verclytte S, et al
    Magnetic resonance imaging changes following natalizumab discontinuation in multiple sclerosis patients with progressive multifocal leukoencephalopathy.
    Mult Scler. 2018 Jan 1:1352458517750765. doi: 10.1177/1352458517750765.
    PubMed     Text format     Abstract available


  65. BOVE R, Healy BC, Musallam A, Soltany P, et al
    Fatty acid binding protein-4 is associated with disability in multiple sclerosis patients.
    Mult Scler. 2018 Jan 1:1352458517750768. doi: 10.1177/1352458517750768.
    PubMed     Text format     Abstract available


  66. RIMKUS CM, Schoonheim MM, Steenwijk MD, Vrenken H, et al
    Gray matter networks and cognitive impairment in multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458517751650. doi: 10.1177/1352458517751650.
    PubMed     Text format     Abstract available


  67. COHEN JA, Hunter SF, Brown TR, Gudesblatt M, et al
    Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial.
    Mult Scler. 2018 Jan 1:1352458518754716. doi: 10.1177/1352458518754716.
    PubMed     Text format     Abstract available


  68. FORD HL, Wicks CR, Stroud A, Tennant A, et al
    Psychological determinants of job retention in multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458518754362. doi: 10.1177/1352458518754362.
    PubMed     Text format     Abstract available


  69. ROY S, Drake A, Fuchs T, Dwyer MG, et al
    Longitudinal personality change associated with cognitive decline in multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458517753720. doi: 10.1177/1352458517753720.
    PubMed     Text format     Abstract available


  70. HAUPTS MR, Spill-Askeridis P, Humpert M, Seidel D, et al
    Acute exacerbations after decades of non-active chronic multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458518754365. doi: 10.1177/1352458518754365.
    PubMed     Text format    


  71. DI IOIA M, Farina D, di Tommaso V, Travaglini D, et al
    Simultaneous early-onset severe autoimmune hemolytic anemia and albuminuria during alemtuzumab treatment for multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458517743093. doi: 10.1177/1352458517743093.
    PubMed     Text format     Abstract available


  72. MEUNIER B, Rico A, Seguier J, Boutiere C, et al
    Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.
    Mult Scler. 2018 Jan 1:1352458517729766. doi: 10.1177/1352458517729766.
    PubMed     Text format     Abstract available


  73. MONTALBAN X, Gold R, Thompson AJ, Otero-Romero S, et al
    ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458517751049. doi: 10.1177/1352458517751049.
    PubMed     Text format     Abstract available


  74. LAVERY AM, Collins BN, Waldman AT, Hart CN, et al
    The contribution of secondhand tobacco smoke exposure to pediatric multiple sclerosis risk.
    Mult Scler. 2018 Jan 1:1352458518757089. doi: 10.1177/1352458518757089.
    PubMed     Text format     Abstract available


    December 2017
  75. KROTH J, Ciolac D, Fleischer V, Koirala N, et al
    Increased cerebrospinal fluid albumin and immunoglobulin A fractions forecast cortical atrophy and longitudinal functional deterioration in relapsing-remitting multiple sclerosis.
    Mult Scler. 2017 Dec 1:1352458517748474. doi: 10.1177/1352458517748474.
    PubMed     Text format     Abstract available


  76. HUGOS CL, Chen Z, Chen Y, Turner AP, et al
    A multicenter randomized controlled trial of two group education programs for fatigue in multiple sclerosis: Short- and medium-term benefits.
    Mult Scler. 2017 Dec 1:1352458517745723. doi: 10.1177/1352458517745723.
    PubMed     Text format     Abstract available


  77. CALLESEN J, Richter C, Kristensen C, Sunesen I, et al
    Test-retest agreement and reliability of the Six Spot Step Test in persons with multiple sclerosis.
    Mult Scler. 2017 Dec 1:1352458517745725. doi: 10.1177/1352458517745725.
    PubMed     Text format     Abstract available


  78. PEETERS LM
    Fair data for next-generation management of multiple sclerosis.
    Mult Scler. 2017 Dec 1:1352458517748475. doi: 10.1177/1352458517748475.
    PubMed     Text format     Abstract available


    November 2017
  79. GRAN-RUAZ S, Mani A, O'Quinn S
    An overview of biosimilars and non-biologic complex drugs in Europe, the United States, and Canada and their relevance to multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517739976. doi: 10.1177/1352458517739976.
    PubMed     Text format     Abstract available


  80. MANCARDI G, Sormani MP, Muraro PA, Boffa G, et al
    Intense immunosuppression followed by autologous haematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517742532. doi: 10.1177/1352458517742532.
    PubMed     Text format     Abstract available


  81. PIETROBONI AM, Dell'Arti L, Caprioli M, Scarioni M, et al
    The loss of macular ganglion cells begins from the early stages of disease and correlates with brain atrophy in multiple sclerosis patients.
    Mult Scler. 2017 Nov 1:1352458517740214. doi: 10.1177/1352458517740214.
    PubMed     Text format     Abstract available


  82. MALHOTRA S, Sorosina M, Rio J, Peroni S, et al
    NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients.
    Mult Scler. 2017 Nov 1:1352458517739137. doi: 10.1177/1352458517739137.
    PubMed     Text format     Abstract available


  83. MALINOVA TS, Dijkstra CD, de Vries HE
    Serotonin: A mediator of the gut-brain axis in multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517739975. doi: 10.1177/1352458517739975.
    PubMed     Text format     Abstract available


  84. ABBOUD H, Hill E, Siddiqui J, Serra A, et al
    Neuromodulation in multiple sclerosis.
    Mult Scler. 2017;23:1663-1676.
    PubMed     Text format     Abstract available


  85. FEYS P, Moumdjian L, Van Halewyck F, Wens I, et al
    Effects of an individual 12-week community-located "start-to-run" program on physical capacity, walking, fatigue, cognitive function, brain volumes, and structures in persons with multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517740211. doi: 10.1177/1352458517740211.
    PubMed     Text format     Abstract available


  86. LOREFICE L, Fenu G, Sardu C, Frau J, et al
    Multiple sclerosis and HLA genotypes: A possible influence on brain atrophy.
    Mult Scler. 2017 Nov 1:1352458517739989. doi: 10.1177/1352458517739989.
    PubMed     Text format     Abstract available


  87. WINGES KM, Murchison CF, Bourdette DN, Spain RI, et al
    Longitudinal optical coherence tomography study of optic atrophy in secondary progressive multiple sclerosis: Results from a clinical trial cohort.
    Mult Scler. 2017 Nov 1:1352458517739136. doi: 10.1177/1352458517739136.
    PubMed     Text format     Abstract available


  88. UHER T, Vaneckova M, Krasensky J, Sobisek L, et al
    Pathological cut-offs of global and regional brain volume loss in multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517742739. doi: 10.1177/1352458517742739.
    PubMed     Text format     Abstract available


  89. KAVALIUNAS A, Danylaite Karrenbauer V, Gyllensten H, Manouchehrinia A, et al
    Cognitive function is a major determinant of income among multiple sclerosis patients in Sweden acting independently from physical disability.
    Mult Scler. 2017 Nov 1:1352458517740212. doi: 10.1177/1352458517740212.
    PubMed     Text format     Abstract available


  90. AGIUS MA, Klodowska-Duda G, Maciejowski M, Potemkowski A, et al
    Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study.
    Mult Scler. 2017 Nov 1:1352458517740641. doi: 10.1177/1352458517740641.
    PubMed     Text format     Abstract available


  91. SPITERI S, Hassa T, Claros-Salinas D, Dettmers C, et al
    Neural correlates of effort-dependent and effort-independent cognitive fatigue components in patients with multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517743090. doi: 10.1177/1352458517743090.
    PubMed     Text format     Abstract available


  92. RICCITELLI GC, Pagani E, Rodegher M, Colombo B, et al
    Imaging patterns of gray and white matter abnormalities associated with PASAT and SDMT performance in relapsing-remitting multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517743091. doi: 10.1177/1352458517743091.
    PubMed     Text format     Abstract available


    October 2017
  93. MOSS-MORRIS R, Norton S
    Aerobic exercise, cognitive behavioural therapy and energy conservation management for multiple sclerosis (MS) fatigue: Are three trials better than one?
    Mult Scler. 2017;23:1436-1440.
    PubMed     Text format    


  94. ZETTERBERG H, Teunissen C
    Fluid biomarkers for disease activity in multiple sclerosis.
    Mult Scler. 2017 Oct 1:1352458517736151. doi: 10.1177/1352458517736151.
    PubMed     Text format    


  95. GIANFRANCESCO MA, Stridh P, Shao X, Rhead B, et al
    Genetic risk factors for pediatric-onset multiple sclerosis.
    Mult Scler. 2017 Oct 1:1352458517733551. doi: 10.1177/1352458517733551.
    PubMed     Text format     Abstract available


  96. FOX RJ, Chataway J
    Advancing trial design in progressive multiple sclerosis.
    Mult Scler. 2017;23:1573-1578.
    PubMed     Text format     Abstract available


  97. MILLER DH, Thompson AJ
    Advancing trial design in progressive multiple sclerosis.
    Mult Scler. 2017;23:1571-1572.
    PubMed     Text format    


  98. MOCCIA M, de Stefano N, Barkhof F
    Imaging outcome measures for progressive multiple sclerosis trials.
    Mult Scler. 2017;23:1614-1626.
    PubMed     Text format     Abstract available


  99. PICHLER A, Khalil M, Langkammer C, Pinter D, et al
    The impact of vascular risk factors on brain volume and lesion load in patients with early multiple sclerosis.
    Mult Scler. 2017 Oct 1:1352458517736149. doi: 10.1177/1352458517736149.
    PubMed     Text format     Abstract available


  100. GLAZER CH, Tottenborg SS, Giwercman A, Brauner EV, et al
    Male factor infertility and risk of multiple sclerosis: A register-based cohort study.
    Mult Scler. 2017 Oct 1:1352458517734069. doi: 10.1177/1352458517734069.
    PubMed     Text format     Abstract available


  101. TINELLI M, Kanavos P, Efthymiadou O, Visintin E, et al
    Using IMPrESS to guide policy change in multiple sclerosis.
    Mult Scler. 2017 Oct 1:1352458517737388. doi: 10.1177/1352458517737388.
    PubMed     Text format     Abstract available


  102. DONADIEU M, Le Fur Y, Maarouf A, Gherib S, et al
    Metabolic counterparts of sodium accumulation in multiple sclerosis: A whole brain 23Na-MRI and fast 1H-MRSI study.
    Mult Scler. 2017 Oct 1:1352458517736146. doi: 10.1177/1352458517736146.
    PubMed     Text format     Abstract available


  103. FLEMING J, Hernandez G, Hartman L, Maksimovic J, et al
    Safety and efficacy of helminth treatment in relapsing-remitting multiple sclerosis: Results of the HINT 2 clinical trial.
    Mult Scler. 2017 Oct 1:1352458517736377. doi: 10.1177/1352458517736377.
    PubMed     Text format     Abstract available


  104. BSTEH G, Hegen H, Teuchner B, Amprosi M, et al
    Peripapillary retinal nerve fibre layer as measured by optical coherence tomography is a prognostic biomarker not only for physical but also for cognitive disability progression in multiple sclerosis.
    Mult Scler. 2017 Oct 1:1352458517740216. doi: 10.1177/1352458517740216.
    PubMed     Text format     Abstract available


  105. LEAVITT VM, Blanchard AR, Guo CY, Gelernt E, et al
    Aspirin is an effective pretreatment for exercise in multiple sclerosis: A double-blind randomized controlled pilot trial.
    Mult Scler. 2017 Oct 1:1352458517739138. doi: 10.1177/1352458517739138.
    PubMed     Text format     Abstract available


  106. DEKKER I, Sombekke MH, Witte BI, Geurts JJ, et al
    Asymptomatic spinal cord lesions do not predict the time to disability in patients with early multiple sclerosis.
    Mult Scler. 2017 Oct 1:1352458517736147. doi: 10.1177/1352458517736147.
    PubMed     Text format     Abstract available


    September 2017
  107. TOBYNE SM, Ochoa WB, Bireley JD, Smith VM, et al
    Cognitive impairment and the regional distribution of cerebellar lesions in multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517730132. doi: 10.1177/1352458517730132.
    PubMed     Text format     Abstract available


  108. FAZIA T, Pastorino R, Foco L, Han L, et al
    Investigating multiple sclerosis genetic susceptibility on the founder population of east-central Sardinia via association and linkage analysis of immune-related loci.
    Mult Scler. 2017 Sep 1:1352458517732841. doi: 10.1177/1352458517732841.
    PubMed     Text format     Abstract available


  109. HUPPKE P, Huppke B, Ellenberger D, Rostasy K, et al
    Therapy of highly active pediatric multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517732843. doi: 10.1177/1352458517732843.
    PubMed     Text format     Abstract available


  110. LANZILLO R, Cennamo G, Criscuolo C, Carotenuto A, et al
    Optical coherence tomography angiography retinal vascular network assessment in multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517729463. doi: 10.1177/1352458517729463.
    PubMed     Text format     Abstract available


  111. COMBER L, Quinn G, McGuigan C, Galvin R, et al
    Medication usage and falls in people with multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517731912. doi: 10.1177/1352458517731912.
    PubMed     Text format     Abstract available


  112. MEINL I, Havla J, Hohlfeld R, Kumpfel T, et al
    Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517731913. doi: 10.1177/1352458517731913.
    PubMed     Text format     Abstract available


  113. GIOVANNONI G, Wiendl H, Turner B, Umans K, et al
    Circulating lymphocyte levels and relationship with infection status in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta.
    Mult Scler. 2017 Sep 1:1352458517729464. doi: 10.1177/1352458517729464.
    PubMed     Text format     Abstract available


  114. KAPPOS L, Arnold DL, Bar-Or A, Camm AJ, et al
    Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517728343. doi: 10.1177/1352458517728343.
    PubMed     Text format     Abstract available


  115. BISECCO A, Nardo FD, Docimo R, Caiazzo G, et al
    Fatigue in multiple sclerosis: The contribution of resting-state functional connectivity reorganization.
    Mult Scler. 2017 Sep 1:1352458517730932. doi: 10.1177/1352458517730932.
    PubMed     Text format     Abstract available


  116. CHARVET LE, Dobbs B, Shaw MT, Bikson M, et al
    Remotely supervised transcranial direct current stimulation for the treatment of fatigue in multiple sclerosis: Results from a randomized, sham-controlled trial.
    Mult Scler. 2017 Sep 1:1352458517732842. doi: 10.1177/1352458517732842.
    PubMed     Text format     Abstract available


    August 2017
  117. BRUNDIN L, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Sweden.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  118. BATTAGLIA M, Kobelt G, Ponzio M, Berg J, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Italy.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  119. BERGER T, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Austria.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  120. DUBOIS B, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Belgium.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  121. OREJA-GUEVARA C, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Spain.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  122. CALABRESE P, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Switzerland.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  123. UITDEHAAG B, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for the Netherlands.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  124. FLACHENECKER P, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Germany.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  125. KOBELT G, Eriksson J, Phillips G, Berg J, et al
    The burden of multiple sclerosis 2015: Methods of data collection, assessment and analysis of costs, quality of life and symptoms.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  126. PENTEK M, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Hungary.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  127. BOYKO A, Kobelt G, Berg J, Boyko O, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Russia.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  128. RASMUSSEN PV, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Denmark.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  129. LEBRUN-FRENAY C, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for France.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  130. THOMPSON A, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for the United Kingdom.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  131. SELMAJ K, Kobelt G, Berg J, Orlewska E, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Poland.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  132. SA MJ, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Portugal.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  133. HAVRDOVA E, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results of the Czech Republic.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  134. VERMOHLEN V, Schiller P, Schickendantz S, Drache M, et al
    Hippotherapy for patients with multiple sclerosis: A multicenter randomized controlled trial (MS-HIPPO).
    Mult Scler. 2017 Aug 1:1352458517721354. doi: 10.1177/1352458517721354.
    PubMed     Text format     Abstract available


  135. RUHRMANN S, Ewing E, Piket E, Kular L, et al
    Hypermethylation of MIR21 in CD4+ T cells from patients with relapsing-remitting multiple sclerosis associates with lower miRNA-21 levels and concomitant up-regulation of its target genes.
    Mult Scler. 2017 Aug 1:1352458517721356. doi: 10.1177/1352458517721356.
    PubMed     Text format     Abstract available


  136. LAROCCA NG, Hudson LD, Rudick R, Amtmann D, et al
    The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability.
    Mult Scler. 2017 Aug 1:1352458517723718. doi: 10.1177/1352458517723718.
    PubMed     Text format     Abstract available


  137. VAVASOUR IM, Huijskens SC, Li DK, Traboulsee AL, et al
    Global loss of myelin water over 5 years in multiple sclerosis normal-appearing white matter.
    Mult Scler. 2017 Aug 1:1352458517723717. doi: 10.1177/1352458517723717.
    PubMed     Text format     Abstract available


  138. BERGAMASCHI R, Cortese A, Pichiecchio A, Berzolari FG, et al
    Air pollution is associated to the multiple sclerosis inflammatory activity as measured by brain MRI.
    Mult Scler. 2017 Aug 1:1352458517726866. doi: 10.1177/1352458517726866.
    PubMed     Text format     Abstract available


  139. LOUAPRE C, Govindarajan ST, Gianni C, Madigan N, et al
    Heterogeneous pathological processes account for thalamic degeneration in multiple sclerosis: Insights from 7 T imaging.
    Mult Scler. 2017 Aug 1:1352458517726382. doi: 10.1177/1352458517726382.
    PubMed     Text format     Abstract available


  140. SELLEBJERG F, Bornsen L, Ammitzboll C, Nielsen JE, et al
    Defining active progressive multiple sclerosis.
    Mult Scler. 2017 Aug 1:1352458517726592. doi: 10.1177/1352458517726592.
    PubMed     Text format     Abstract available


  141. ZIMMER P, Bloch W, Schenk A, Oberste M, et al
    High-intensity interval exercise improves cognitive performance and reduces matrix metalloproteinases-2 serum levels in persons with multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2017 Aug 1:1352458517728342. doi: 10.1177/1352458517728342.
    PubMed     Text format     Abstract available


  142. SOLOMON AJ, Watts R, Ontaneda D, Absinta M, et al
    Diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.
    Mult Scler. 2017 Aug 1:1352458517726383. doi: 10.1177/1352458517726383.
    PubMed     Text format     Abstract available


  143. AFOLABI D, Albor C, Zalewski L, Altmann DR, et al
    Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis.
    Mult Scler. 2017 Aug 1:1352458517726380. doi: 10.1177/1352458517726380.
    PubMed     Text format     Abstract available


  144. FAISSNER S, Mahjoub Y, Mishra M, Haupeltshofer S, et al
    Unexpected additive effects of minocycline and hydroxychloroquine in models of multiple sclerosis: Prospective combination treatment for progressive disease?
    Mult Scler. 2017 Aug 1:1352458517728811. doi: 10.1177/1352458517728811.
    PubMed     Text format     Abstract available


  145. KALINCIK T, Jokubaitis V, Spelman T, Horakova D, et al
    Cladribine versus fingolimod, natalizumab and interferon beta for multiple sclerosis.
    Mult Scler. 2017 Aug 1:1352458517728812. doi: 10.1177/1352458517728812.
    PubMed     Text format     Abstract available


  146. BOVE R, Chitnis T, Cree BA, Tintore M, et al
    SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts.
    Mult Scler. 2017 Aug 1:1352458517726657. doi: 10.1177/1352458517726657.
    PubMed     Text format     Abstract available


  147. GIOVANNONI G, Soelberg Sorensen P, Cook S, Rammohan K, et al
    Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
    Mult Scler. 2017 Aug 1:1352458517727603. doi: 10.1177/1352458517727603.
    PubMed     Text format     Abstract available


    July 2017
  148. MIGLIORE S, Curcio G, Couyoumdjian A, Ghazaryan A, et al
    Executive functioning in relapsing-remitting multiple sclerosis patients without cognitive impairment: A task-switching protocol.
    Mult Scler. 2017 Jul 1:1352458517719149. doi: 10.1177/1352458517719149.
    PubMed     Text format     Abstract available


  149. KJOLHEDE T, Siemonsen S, Wenzel D, Stellmann JP, et al
    Can resistance training impact MRI outcomes in relapsing-remitting multiple sclerosis?
    Mult Scler. 2017 Jul 1:1352458517722645. doi: 10.1177/1352458517722645.
    PubMed     Text format     Abstract available


  150. TANAKA M, Kinoshita M, Tanaka K
    Intermittent drug holidays in fingolimod therapy for multiple sclerosis.
    Mult Scler. 2017 Jul 1:1352458517722647. doi: 10.1177/1352458517722647.
    PubMed     Text format    


  151. STAMPANONI BASSI M, Leocani L, Comi G, Iezzi E, et al
    Can pharmacological manipulation of LTP favor the effects of motor rehabilitation in multiple sclerosis?
    Mult Scler. 2017 Jul 1:1352458517721358. doi: 10.1177/1352458517721358.
    PubMed     Text format     Abstract available


  152. ROLF L, Muris AH, Mathias A, Du Pasquier R, et al
    Exploring the effect of vitamin D3 supplementation on the anti-EBV antibody response in relapsing-remitting multiple sclerosis.
    Mult Scler. 2017 Jul 1:1352458517722646. doi: 10.1177/1352458517722646.
    PubMed     Text format     Abstract available


  153. BALDASSARI LE, Salter AR, Longbrake EE, Cross AH, et al
    Streamlined EDSS for use in multiple sclerosis clinical practice: Development and cross-sectional comparison to EDSS.
    Mult Scler. 2017 Jul 1:1352458517721357. doi: 10.1177/1352458517721357.
    PubMed     Text format     Abstract available


  154. DUNN N, Juto A, Ryner M, Manouchehrinia A, et al
    Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies.
    Mult Scler. 2017 Jul 1:1352458517720044. doi: 10.1177/1352458517720044.
    PubMed     Text format     Abstract available


  155. CANCELLI A, Cottone C, Giordani A, Migliore S, et al
    Personalized, bilateral whole-body somatosensory cortex stimulation to relieve fatigue in multiple sclerosis.
    Mult Scler. 2017 Jul 1:1352458517720528. doi: 10.1177/1352458517720528.
    PubMed     Text format     Abstract available


    June 2017
  156. CHOI IY, Lee P, Adany P, Hughes AJ, et al
    In vivo evidence of oxidative stress in brains of patients with progressive multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517711568. doi: 10.1177/1352458517711568.
    PubMed     Text format     Abstract available


  157. SATTARNEZHAD N, Farrow S, Kimbrough D, Glanz B, et al
    Agreement analysis comparing iPad LCVA and Sloan testing in multiple sclerosis patients.
    Mult Scler. 2017 Jun 1:1352458517713667. doi: 10.1177/1352458517713667.
    PubMed     Text format     Abstract available


  158. LEE H, Nakamura K, Narayanan S, Brown R, et al
    Impact of immunoablation and autologous hematopoietic stem cell transplantation on gray and white matter atrophy in multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517715811. doi: 10.1177/1352458517715811.
    PubMed     Text format     Abstract available


  159. BOESEN MS, Magyari M, Koch-Henriksen N, Thygesen LC, et al
    Pediatric-onset multiple sclerosis and other acquired demyelinating syndromes of the central nervous system in Denmark during 1977-2015: A nationwide population-based incidence study.
    Mult Scler. 2017 Jun 1:1352458517713669. doi: 10.1177/1352458517713669.
    PubMed     Text format     Abstract available


  160. PAKPOOR J, Seminatore B, Graves JS, Schreiner T, et al
    Dietary factors and pediatric multiple sclerosis: A case-control study.
    Mult Scler. 2017 Jun 1:1352458517713343. doi: 10.1177/1352458517713343.
    PubMed     Text format     Abstract available


  161. SALMEN A
    Clinical commentary on "Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab".
    Mult Scler. 2017 Jun 1:1352458517717810. doi: 10.1177/1352458517717810.
    PubMed     Text format    


  162. MULERO P, Auger C, Parolin L, Fonseca E, et al
    Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab.
    Mult Scler. 2017 Jun 1:1352458517711569. doi: 10.1177/1352458517711569.
    PubMed     Text format     Abstract available


  163. FOLEY RW, Tagg NT, Schindler MK, Fenton KM, et al
    Recurrent natalizumab-related aseptic meningitis in a patient with multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517702533. doi: 10.1177/1352458517702533.
    PubMed     Text format     Abstract available


  164. DOBRYAKOVA E, Hulst HE, Spirou A, Chiaravalloti ND, et al
    Fronto-striatal network activation leads to less fatigue in multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517717087. doi: 10.1177/1352458517717087.
    PubMed     Text format     Abstract available


  165. RANGANATHAN U, Kaunzner U, Foster S, Vartanian T, et al
    Thrombocytopenia at the time of alemtuzumab infusion in relapsing-remitting multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517719152. doi: 10.1177/1352458517719152.
    PubMed     Text format    


  166. YAP SM, McNicholas N, Hutchinson M, McGuigan C, et al
    Immediate thrombocytopenia at time of alemtuzumab infusion for multiple sclerosis - Not always self-limiting, fully reversible or predictable.
    Mult Scler. 2017 Jun 1:1352458517719151. doi: 10.1177/1352458517719151.
    PubMed     Text format    


  167. WEYGANDT M, Wakonig K, Behrens J, Meyer-Arndt L, et al
    Brain activity, regional gray matter loss, and decision-making in multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517717089. doi: 10.1177/1352458517717089.
    PubMed     Text format     Abstract available


  168. HIDALGO DE LA CRUZ M, d'Ambrosio A, Valsasina P, Pagani E, et al
    Abnormal functional connectivity of thalamic sub-regions contributes to fatigue in multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517717807. doi: 10.1177/1352458517717807.
    PubMed     Text format     Abstract available


  169. RUANO L, Branco M, Portaccio E, Goretti B, et al
    Patients with paediatric-onset multiple sclerosis are at higher risk of cognitive impairment in adulthood: An Italian collaborative study.
    Mult Scler. 2017 Jun 1:1352458517717341. doi: 10.1177/1352458517717341.
    PubMed     Text format     Abstract available


  170. BOZ C, Terzi M, Zengin Karahan S, Sen S, et al
    Safety of IV pulse methylprednisolone therapy during breastfeeding in patients with multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517717806. doi: 10.1177/1352458517717806.
    PubMed     Text format     Abstract available


    May 2017
  171. GOVEROVER Y, Chiaravalloti N, Genova H, DeLuca J, et al
    A randomized controlled trial to treat impaired learning and memory in multiple sclerosis: The self-GEN trial.
    Mult Scler. 2017 May 1:1352458517709955. doi: 10.1177/1352458517709955.
    PubMed     Text format     Abstract available


  172. BENEDICT RH, Cohan S, Lynch SG, Riester K, et al
    Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study.
    Mult Scler. 2017 May 1:1352458517707345. doi: 10.1177/1352458517707345.
    PubMed     Text format     Abstract available


  173. FREILICH J, Manouchehrinia A, Trusheim M, Baird LG, et al
    Characterization of annual disease progression of multiple sclerosis patients: A population-based study.
    Mult Scler. 2017 May 1:1352458517706252. doi: 10.1177/1352458517706252.
    PubMed     Text format     Abstract available


  174. ZEYDAN B, Lowe VJ, Schwarz CG, Przybelski SA, et al
    Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517707346. doi: 10.1177/1352458517707346.
    PubMed     Text format     Abstract available


  175. SHINODA K, Matsushita T, Nakamura Y, Masaki K, et al
    HLA-DRB1*04:05 allele is associated with intracortical lesions on three-dimensional double inversion recovery images in Japanese patients with multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517707067. doi: 10.1177/1352458517707067.
    PubMed     Text format     Abstract available


  176. SALTER A, Thomas NP, Tyry T, Cutter GR, et al
    A contemporary profile of primary progressive multiple sclerosis participants from the NARCOMS Registry.
    Mult Scler. 2017 May 1:1352458517711274. doi: 10.1177/1352458517711274.
    PubMed     Text format     Abstract available


  177. SUMOWSKI JF, Leavitt VM, Rocca MA, Inglese M, et al
    Mesial temporal lobe and subcortical grey matter volumes differentially predict memory across stages of multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517708873. doi: 10.1177/1352458517708873.
    PubMed     Text format     Abstract available


  178. CAWLEY N, Tur C, Prados F, Plantone D, et al
    Spinal cord atrophy as a primary outcome measure in phase II trials of progressive multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517709954. doi: 10.1177/1352458517709954.
    PubMed     Text format     Abstract available


  179. BALK LJ, Coric D, Nij Bijvank JA, Killestein J, et al
    Retinal atrophy in relation to visual functioning and vision-related quality of life in patients with multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517708463. doi: 10.1177/1352458517708463.
    PubMed     Text format     Abstract available


  180. PRINEAS JW, Parratt JDE
    Multiple sclerosis: Serum anti-CNS autoantibodies.
    Mult Scler. 2017 May 1:1352458517706037. doi: 10.1177/1352458517706037.
    PubMed     Text format     Abstract available


  181. PALOTAI M, Mike A, Cavallari M, Strammer E, et al
    Changes to the septo-fornical area might play a role in the pathogenesis of anxiety in multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517711273. doi: 10.1177/1352458517711273.
    PubMed     Text format     Abstract available


  182. MARINO M, Frisullo G, Di Sante G, Samengo DM, et al
    Low reliability of anti-KIR4.183-120 peptide auto-antibodies in multiple sclerosis patients.
    Mult Scler. 2017 May 1:1352458517711275. doi: 10.1177/1352458517711275.
    PubMed     Text format     Abstract available


  183. REDONDO J, Sarkar P, Kemp K, Virgo PF, et al
    Reduced cellularity of bone marrow in multiple sclerosis with decreased MSC expansion potential and premature ageing in vitro.
    Mult Scler. 2017 May 1:1352458517711276. doi: 10.1177/1352458517711276.
    PubMed     Text format     Abstract available


  184. BIBERACHER V, Schmidt P, Selter RC, Pernpeinter V, et al
    Fatigue in multiple sclerosis: Associations with clinical, MRI and CSF parameters.
    Mult Scler. 2017 May 1:1352458517712078. doi: 10.1177/1352458517712078.
    PubMed     Text format     Abstract available


  185. SMOOT K, Spinelli KJ, Stuchiner T, Lucas L, et al
    Three-year clinical outcomes of relapsing multiple sclerosis patients treated with dimethyl fumarate in a United States community health center.
    Mult Scler. 2017 May 1:1352458517709956. doi: 10.1177/1352458517709956.
    PubMed     Text format     Abstract available


  186. TORTORELLA C, Direnzo V, Ruggieri M, Zoccolella S, et al
    Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517711774. doi: 10.1177/1352458517711774.
    PubMed     Text format     Abstract available


  187. VAN DER VUURST DE VRIES RM, van den Dorpel JJ, Mescheriakova JY, Runia TF, et al
    Fatigue after a first attack of suspected multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517709348. doi: 10.1177/1352458517709348.
    PubMed     Text format     Abstract available


  188. VAN DEN AKKER LE, Beckerman H, Collette EH, Twisk JW, et al
    Cognitive behavioral therapy positively affects fatigue in patients with multiple sclerosis: Results of a randomized controlled trial.
    Mult Scler. 2017 May 1:1352458517709361. doi: 10.1177/1352458517709361.
    PubMed     Text format     Abstract available


  189. HEINE M, Verschuren O, Hoogervorst EL, van Munster E, et al
    Does aerobic training alleviate fatigue and improve societal participation in patients with multiple sclerosis? A randomized controlled trial.
    Mult Scler. 2017 May 1:1352458517696596. doi: 10.1177/1352458517696596.
    PubMed     Text format     Abstract available


  190. BLIKMAN LJ, van Meeteren J, Twisk JW, de Laat FA, et al
    Effectiveness of energy conservation management on fatigue and participation in multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2017 May 1:1352458517702751. doi: 10.1177/1352458517702751.
    PubMed     Text format     Abstract available


  191. KAPPOS L, Butzkueven H, Wiendl H, Spelman T, et al
    Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study.
    Mult Scler. 2017 May 1:1352458517709619. doi: 10.1177/1352458517709619.
    PubMed     Text format     Abstract available


  192. SORMANI MP
    Why non-inferiority is more challenging than superiority?
    Mult Scler. 2017;23:790-791.
    PubMed     Text format     Abstract available


  193. HOEPNER R, Kolb EM, Dahlhaus S, Hellwig K, et al
    Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy.
    Mult Scler. 2017;23:830-835.
    PubMed     Text format     Abstract available


  194. PITTERI M, Romualdi C, Magliozzi R, Monaco S, et al
    Cognitive impairment predicts disability progression and cortical thinning in MS: An 8-year study.
    Mult Scler. 2017;23:848-854.
    PubMed     Text format     Abstract available


    April 2017
  195. COETZEE T, Thompson A
    When are we going to take modifiable risk factors more seriously in multiple sclerosis?
    Mult Scler. 2017;23:494-495.
    PubMed     Text format    


  196. AL-LOUZI O, Button J, Newsome SD, Calabresi PA, et al
    Retrograde trans-synaptic visual pathway degeneration in multiple sclerosis: A case series.
    Mult Scler. 2017 Apr 1:1352458516679035. doi: 10.1177/1352458516679035.
    PubMed     Text format     Abstract available


  197. SOLARI A, Giordano A, Patti F, Grasso MG, et al
    Randomized controlled trial of a home-based palliative approach for people with severe multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458517704078. doi: 10.1177/1352458517704078.
    PubMed     Text format     Abstract available


  198. COHEN JA, Imrey PB, Planchon SM, Bermel RA, et al
    Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458517703802. doi: 10.1177/1352458517703802.
    PubMed     Text format     Abstract available


  199. GIOVANNONI G, Tomic D, Bright JR, Havrdova E, et al
    "No evident disease activity": The use of combined assessments in the management of patients with multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458517703193. doi: 10.1177/1352458517703193.
    PubMed     Text format     Abstract available


  200. MORANDI E, Tarlinton RE, Tanasescu R, Gran B, et al
    Human endogenous retroviruses and multiple sclerosis: Causation, association, or after-effect?
    Mult Scler. 2017 Apr 1:1352458517704711. doi: 10.1177/1352458517704711.
    PubMed     Text format     Abstract available


  201. KLAUSER AM, Wiebenga OT, Eijlers AJ, Schoonheim MM, et al
    Metabolites predict lesion formation and severity in relapsing-remitting multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458517702534. doi: 10.1177/1352458517702534.
    PubMed     Text format     Abstract available


  202. AMATO MP
    The diagnostic dilemma of multiple sclerosis presenting with isolated cognitive and behavioral disorders.
    Mult Scler. 2017 Apr 1:1352458517705002. doi: 10.1177/1352458517705002.
    PubMed     Text format     Abstract available


  203. ZAMBON AA, Cecchetti G, Caso F, Santangelo R, et al
    Primary progressive multiple sclerosis presenting with severe predominant cognitive impairment and psychiatric symptoms: A challenging case.
    Mult Scler. 2017 Apr 1:1352458517702550. doi: 10.1177/1352458517702550.
    PubMed     Text format     Abstract available


  204. CIAMPI E, Uribe-San-Martin R, Godoy-Santin J, Cruz JP, et al
    Secondary paroxysmal dyskinesia in multiple sclerosis: Clinical-radiological features and treatment. Case report of seven patients.
    Mult Scler. 2017 Apr 1:1352458517702968. doi: 10.1177/1352458517702968.
    PubMed     Text format     Abstract available


  205. POP R, Kipfer S
    Paroxysmal kinesigenic dyskinesia-like phenotype in multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458517702535. doi: 10.1177/1352458517702535.
    PubMed     Text format     Abstract available


  206. PAREES I
    Clinical commentary on "Paroxysmal kinesigenic dyskinesia-like phenotype in multiple sclerosis" and "Secondary paroxysmal dyskinesia in multiple sclerosis: Clinical-radiological features and treatment. Case report of seven patients".
    Mult Scler. 2017 Apr 1:1352458517702555. doi: 10.1177/1352458517702555.
    PubMed     Text format     Abstract available


  207. BODINI B, Branzoli F, Poirion E, Garcia-Lorenzo D, et al
    Dysregulation of energy metabolism in multiple sclerosis measured in vivo with diffusion-weighted spectroscopy.
    Mult Scler. 2017 Apr 1:1352458517698249. doi: 10.1177/1352458517698249.
    PubMed     Text format     Abstract available


  208. KOLBER P, Droby A, Roebroeck A, Goebel R, et al
    A "kissing lesion": In-vivo 7T evidence of meningeal inflammation in early multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458516683267. doi: 10.1177/1352458516683267.
    PubMed     Text format     Abstract available


  209. KILSDONK ID, Schoonheim M, Wattjes MP
    In-vivo imaging of meningeal inflammation in multiple sclerosis: Presence of evidence or evidence of presence?
    Mult Scler. 2017 Apr 1:1352458517704924. doi: 10.1177/1352458517704924.
    PubMed     Text format    


  210. TOUSSAINT-DUYSTER LC, Wong YYM, Van der Cammen-van Zijp MH, Van Pelt-Gravesteijn D, et al
    Fatigue and physical functioning in children with multiple sclerosis and acute disseminated encephalomyelitis.
    Mult Scler. 2017 Apr 1:1352458517706038. doi: 10.1177/1352458517706038.
    PubMed     Text format     Abstract available


  211. HAGENS MH, Killestein J, Yaqub MM, van Dongen GA, et al
    Cerebral rituximab uptake in multiple sclerosis: A 89Zr-immunoPET pilot study.
    Mult Scler. 2017 Apr 1:1352458517704507. doi: 10.1177/1352458517704507.
    PubMed     Text format     Abstract available


  212. SORMANI MP
    Indirect comparisons of treatment effects: Network meta-analyses.
    Mult Scler. 2017;23:510-512.
    PubMed     Text format     Abstract available


  213. BOUDOT DE LA MOTTE M, Louapre C, Bertrand A, Reach P, et al
    Extensive white matter lesions after 2 years of fingolimod: Progressive multifocal leukoencephalopathy or MS relapse?
    Mult Scler. 2017;23:614-616.
    PubMed     Text format     Abstract available


  214. AIRAS L, Rissanen E, Rinne J
    Imaging of microglial activation in MS using PET: Research use and potential future clinical application.
    Mult Scler. 2017;23:496-504.
    PubMed     Text format     Abstract available


  215. HUM S, Lapierre Y, Scott SC, Duquette P, et al
    Trajectory of MS disease course for men and women over three eras.
    Mult Scler. 2017;23:534-545.
    PubMed     Text format     Abstract available


  216. D'SOUZA M, Yaldizli O, John R, Vogt DR, et al
    Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study.
    Mult Scler. 2017;23:597-603.
    PubMed     Text format     Abstract available


  217. VERMERSCH P, Hobart J, Dive-Pouletty C, Bozzi S, et al
    Measuring treatment satisfaction in MS: Is the Treatment Satisfaction Questionnaire for Medication fit for purpose?
    Mult Scler. 2017;23:604-613.
    PubMed     Text format     Abstract available


  218. CIAMPI E, Pareto D, Sastre-Garriga J, Vidal-Jordana A, et al
    Grey matter atrophy is associated with disability increase in natalizumab-treated patients.
    Mult Scler. 2017;23:556-566.
    PubMed     Text format     Abstract available


  219. BROWNLEE WJ, Altmann DR, Alves Da Mota P, Swanton JK, et al
    Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome.
    Mult Scler. 2017;23:665-674.
    PubMed     Text format     Abstract available


  220. SORMANI MP, Kappos L, Radue EW, Cohen J, et al
    Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS.
    Mult Scler. 2017;23:656-664.
    PubMed     Text format     Abstract available


    March 2017
  221. BOGIE JF, Boelen E, Louagie E, Delputte P, et al
    CD169 is a marker for highly pathogenic phagocytes in multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517698759. doi: 10.1177/1352458517698759.
    PubMed     Text format     Abstract available


  222. PITAROKOILI K, Hellwig K, Lukas C, Gold R, et al
    Successful pregnancy after natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis.
    Mult Scler. 2017;23:483-486.
    PubMed     Text format     Abstract available


  223. ARRAMBIDE G
    Commentary on "Successful pregnancy after natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis".
    Mult Scler. 2017;23:486-487.
    PubMed     Text format    


  224. MARRIE RA
    What is the risk of suicide in multiple sclerosis?
    Mult Scler. 2017 Mar 1:1352458517699992. doi: 10.1177/1352458517699992.
    PubMed     Text format    


  225. KALSON-RAY S, Edan G, Leray E
    An excessive risk of suicide may no longer be a reality for multiple sclerosis patients.
    Mult Scler. 2017 Mar 1:1352458517699873. doi: 10.1177/1352458517699873.
    PubMed     Text format     Abstract available


  226. LEURS CE, Podlesniy P, Trullas R, Balk L, et al
    Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment.
    Mult Scler. 2017 Mar 1:1352458517699874. doi: 10.1177/1352458517699874.
    PubMed     Text format     Abstract available


  227. ROCCA MA, Valsasina P, Leavitt VM, Rodegher M, et al
    Functional network connectivity abnormalities in multiple sclerosis: Correlations with disability and cognitive impairment.
    Mult Scler. 2017 Mar 1:1352458517699875. doi: 10.1177/1352458517699875.
    PubMed     Text format     Abstract available


  228. RIO J, Rovira A, Tintore M, Otero-Romero S, et al
    Disability progression markers over 6-12 years in interferon-beta-treated multiple sclerosis patients.
    Mult Scler. 2017 Mar 1:1352458517698052. doi: 10.1177/1352458517698052.
    PubMed     Text format     Abstract available


  229. CORTESE M, Riise T, Bjornevik K, Myhr KM, et al
    Body size and physical exercise, and the risk of multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517699289. doi: 10.1177/1352458517699289.
    PubMed     Text format     Abstract available


  230. RANGANATHAN U, Kaunzner U, Foster S, Vartanian T, et al
    Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517699876. doi: 10.1177/1352458517699876.
    PubMed     Text format     Abstract available


  231. FEINSTEIN A, Pavisian B
    Multiple sclerosis and suicide.
    Mult Scler. 2017 Mar 1:1352458517702553. doi: 10.1177/1352458517702553.
    PubMed     Text format     Abstract available


  232. CHARVET LE, Shaw M, Frontario A, Langdon D, et al
    Cognitive impairment in pediatric-onset multiple sclerosis is detected by the Brief International Cognitive Assessment for Multiple Sclerosis and computerized cognitive testing.
    Mult Scler. 2017 Mar 1:1352458517701588. doi: 10.1177/1352458517701588.
    PubMed     Text format     Abstract available


  233. HOUTCHENS MK, Zapata LB, Curtis KM, Whiteman MK, et al
    Contraception for women with multiple sclerosis: Guidance for healthcare providers.
    Mult Scler. 2017 Mar 1:1352458517701314. doi: 10.1177/1352458517701314.
    PubMed     Text format     Abstract available


  234. RUGGIERI S, Fanelli F, Castelli L, Petsas N, et al
    Lesion symptom map of cognitive-postural interference in multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517701313. doi: 10.1177/1352458517701313.
    PubMed     Text format     Abstract available


  235. TOURBAH A, Sedel F
    Reply to the letter: Biotinidase deficiency masquerading as multiple sclerosis?
    Mult Scler. 2017 Mar 1:1352458517702554. doi: 10.1177/1352458517702554.
    PubMed     Text format    


  236. WOLF B
    Biotinidase deficiency masquerading as multiple sclerosis?
    Mult Scler. 2017 Mar 1:1352458517702551. doi: 10.1177/1352458517702551.
    PubMed     Text format    


  237. GYLLENSTEN H, Wiberg M, Alexanderson K, Friberg E, et al
    Comparing costs of illness of multiple sclerosis in three different years: A population-based study.
    Mult Scler. 2017 Mar 1:1352458517702549. doi: 10.1177/1352458517702549.
    PubMed     Text format     Abstract available


  238. INEICHEN BV, Schneider MP, Hlavica M, Hagenbuch N, et al
    High EDSS can predict risk for upper urinary tract damage in patients with multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517703801. doi: 10.1177/1352458517703801.
    PubMed     Text format     Abstract available


  239. SORMANI MP
    Prognostic factors versus markers of response to treatment versus surrogate endpoints: Three different concepts.
    Mult Scler. 2017;23:378-381.
    PubMed     Text format     Abstract available


  240. GRAVES JS, Chohan H, Cedars B, Arnow S, et al
    Sex differences and subclinical retinal injury in pediatric-onset MS.
    Mult Scler. 2017;23:447-455.
    PubMed     Text format     Abstract available


    February 2017
  241. HEMPEL S, Graham GD, Fu N, Estrada E, et al
    A systematic review of the effects of modifiable risk factor interventions on the progression of multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690271. doi: 10.1177/1352458517690271.
    PubMed     Text format     Abstract available


  242. HEMPEL S, Graham GD, Fu N, Estrada E, et al
    A systematic review of modifiable risk factors in the progression of multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690270. doi: 10.1177/1352458517690270.
    PubMed     Text format     Abstract available


  243. PRAVATA E, Rocca MA, Valsasina P, Riccitelli GC, et al
    Gray matter trophism, cognitive impairment, and depression in patients with multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517692886. doi: 10.1177/1352458517692886.
    PubMed     Text format     Abstract available


  244. CARPENTER AF, Goodwin SJ, Bornstein PF, Larson AJ, et al
    Cutaneous cryptococcosis in a patient taking fingolimod for multiple sclerosis: Here come the opportunistic infections?
    Mult Scler. 2017;23:297-299.
    PubMed     Text format     Abstract available


  245. CAMERON MH, McMillan G
    Methylphenidate is likely less effective than placebo for improving imbalance, walking, and fatigue in people with multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517692421. doi: 10.1177/1352458517692421.
    PubMed     Text format    


  246. SONNENBERG A, Ajdacic-Gross V
    Similar birth-cohort patterns in Crohn's disease and multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517691620. doi: 10.1177/1352458517691620.
    PubMed     Text format     Abstract available


  247. BALCER LJ, Raynowska J, Nolan R, Galetta SL, et al
    Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690822. doi: 10.1177/1352458517690822.
    PubMed     Text format     Abstract available


  248. MOTL RW, Cohen JA, Benedict R, Phillips G, et al
    Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690823. doi: 10.1177/1352458517690823.
    PubMed     Text format     Abstract available


  249. BENEDICT RH, DeLuca J, Phillips G, LaRocca N, et al
    Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690821. doi: 10.1177/1352458517690821.
    PubMed     Text format     Abstract available


  250. FEYS P, Lamers I, Francis G, Benedict R, et al
    The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690824. doi: 10.1177/1352458517690824.
    PubMed     Text format     Abstract available


  251. HULST HE, Thompson AJ, Geurts JJ
    The measure tells the tale: Clinical outcome measures in multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690825. doi: 10.1177/1352458517690825.
    PubMed     Text format    


  252. SHOR N, Amador MD, Dormont D, Lubetzki C, et al
    Involvement of peripheral III nerve in multiple sclerosis patient: Report of a new case and discussion of the underlying mechanism.
    Mult Scler. 2017 Feb 1:1352458516687401. doi: 10.1177/1352458516687401.
    PubMed     Text format     Abstract available


  253. ROVIRA A
    Peripheral nervous system involvement in multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517693469. doi: 10.1177/1352458517693469.
    PubMed     Text format    


  254. CORIC D, Balk LJ, Verrijp M, Eijlers A, et al
    Cognitive impairment in patients with multiple sclerosis is associated with atrophy of the inner retinal layers.
    Mult Scler. 2017 Feb 1:1352458517694090. doi: 10.1177/1352458517694090.
    PubMed     Text format     Abstract available


  255. GIACOMINI E, Rizzo F, Etna MP, Cruciani M, et al
    Thymosin-alpha1 expands deficient IL-10-producing regulatory B cell subsets in relapsing-remitting multiple sclerosis patients.
    Mult Scler. 2017 Feb 1:1352458517695892. doi: 10.1177/1352458517695892.
    PubMed     Text format     Abstract available


  256. GALAZKA G, Mycko MP, Selmaj I, Raine CS, et al
    Multiple sclerosis: Serum-derived exosomes express myelin proteins.
    Mult Scler. 2017 Feb 1:1352458517696597. doi: 10.1177/1352458517696597.
    PubMed     Text format     Abstract available


  257. MAILLEUX J, Vanmierlo T, Bogie JF, Wouters E, et al
    Active liver X receptor signaling in phagocytes in multiple sclerosis lesions.
    Mult Scler. 2017 Feb 1:1352458517696595. doi: 10.1177/1352458517696595.
    PubMed     Text format     Abstract available


  258. ROY S, Drake AS, Eizaguirre MB, Zivadinov R, et al
    Trait neuroticism, extraversion, and conscientiousness in multiple sclerosis: Link to cognitive impairment?
    Mult Scler. 2017 Feb 1:1352458517695467. doi: 10.1177/1352458517695467.
    PubMed     Text format     Abstract available


  259. SCHWARTZ CE, Grover SA, Powell VE, Noguera A, et al
    Risk factors for non-adherence to disease-modifying therapy in pediatric multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517695469. doi: 10.1177/1352458517695469.
    PubMed     Text format     Abstract available


  260. CACAO G, Santos E, Martins Silva A
    Concurrent autoimmune hepatitis in multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517692885. doi: 10.1177/1352458517692885.
    PubMed     Text format     Abstract available


  261. GOLAN D, Doniger GM, Wissemann K, Zarif M, et al
    The impact of subjective cognitive fatigue and depression on cognitive function in patients with multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517695470. doi: 10.1177/1352458517695470.
    PubMed     Text format     Abstract available


  262. ZECCA C, Merlini A, Disanto G, Rodegher M, et al
    Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study.
    Mult Scler. 2017 Feb 1:1352458517694089. doi: 10.1177/1352458517694089.
    PubMed     Text format     Abstract available


  263. KOBELT G, Thompson A, Berg J, Gannedahl M, et al
    New insights into the burden and costs of multiple sclerosis in Europe.
    Mult Scler. 2017 Feb 1:1352458517694432. doi: 10.1177/1352458517694432.
    PubMed     Text format     Abstract available


  264. WESNES K, Myhr KM, Riise T, Cortese M, et al
    Physical activity is associated with a decreased multiple sclerosis risk: The EnvIMS study.
    Mult Scler. 2017 Feb 1:1352458517694088. doi: 10.1177/1352458517694088.
    PubMed     Text format     Abstract available


  265. PATEL VP, Walker LA, Feinstein A
    Revisiting cognitive reserve and cognition in multiple sclerosis: A closer look at depression.
    Mult Scler. 2017 Feb 1:1352458517692887. doi: 10.1177/1352458517692887.
    PubMed     Text format     Abstract available


  266. CLERICO M, De Mercanti S, Artusi CA, Durelli L, et al
    Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab.
    Mult Scler. 2017 Feb 1:1352458516688350. doi: 10.1177/1352458516688350.
    PubMed     Text format     Abstract available


  267. SHEIKH-TAHA M, Corman LC
    Pulmonary Nocardia beijingensis infection associated with the use of alemtuzumab in a patient with multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517694431. doi: 10.1177/1352458517694431.
    PubMed     Text format     Abstract available


  268. BACCHETTA F, Mathias A, Schluep M, Du Pasquier R, et al
    Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence.
    Mult Scler. 2017;23:300-303.
    PubMed     Text format     Abstract available


  269. SORMANI MP, Bruzzi P
    Estimating a treatment effect: Choosing between relative and absolute measures.
    Mult Scler. 2017;23:197-200.
    PubMed     Text format     Abstract available


  270. SORMANI MP, Muraro PA, Saccardi R, Mancardi G, et al
    NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs.
    Mult Scler. 2017;23:201-204.
    PubMed     Text format     Abstract available


    January 2017
  271. AMATO MP, Derfuss T, Hemmer B, Liblau R, et al
    Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop.
    Mult Scler. 2017 Jan 6:1352458516686847. doi: 10.1177/1352458516686847.
    PubMed     Text format     Abstract available


  272. GONZALEZ TORRE JA, Cruz-Gomez AJ, Belenguer A, Sanchis-Segura C, et al
    Hippocampal dysfunction is associated with memory impairment in multiple sclerosis: A volumetric and functional connectivity study.
    Mult Scler. 2017 Jan 1:1352458516688349. doi: 10.1177/1352458516688349.
    PubMed     Text format     Abstract available


  273. MUNOZ MA, Kulick CG, Kortepeter CM, Levin RL, et al
    Liver injury associated with dimethyl fumarate in multiple sclerosis patients.
    Mult Scler. 2017 Jan 1:1352458516688351. doi: 10.1177/1352458516688351.
    PubMed     Text format     Abstract available


  274. MOTL RW, Mowry EM, Ehde DM, LaRocca NG, et al
    Wellness and multiple sclerosis: The National MS Society establishes a Wellness Research Working Group and research priorities.
    Mult Scler. 2017 Jan 1:1352458516687404. doi: 10.1177/1352458516687404.
    PubMed     Text format     Abstract available


  275. SUN H
    Temperature dependence of multiple sclerosis mortality rates in the United States.
    Mult Scler. 2017 Jan 1:1352458516688954. doi: 10.1177/1352458516688954.
    PubMed     Text format     Abstract available


  276. LEAVITT VM, Buyukturkoglu K, Inglese M, Sumowski JF, et al
    Protective personality traits: High openness and low neuroticism linked to better memory in multiple sclerosis.
    Mult Scler. 2017 Jan 1:1352458516685417. doi: 10.1177/1352458516685417.
    PubMed     Text format     Abstract available


  277. SONG J, Karrenbauer V, Manouchehrinia A, Almqvist C, et al
    Similar familial risk in multiple sclerosis subgroups.
    Mult Scler. 2017 Jan 1:1352458516684214. doi: 10.1177/1352458516684214.
    PubMed     Text format     Abstract available


  278. DE STEFANO N, Giorgio A, Battaglini M, De Leucio A, et al
    Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets.
    Mult Scler. 2017 Jan 1:1352458517690269. doi: 10.1177/1352458517690269.
    PubMed     Text format     Abstract available


  279. MA AY, Vitorino RC, Hojjat SP, Mulholland AD, et al
    The relationship between white matter fiber damage and gray matter perfusion in large-scale functionally defined networks in multiple sclerosis.
    Mult Scler. 2017 Jan 1:1352458517691149. doi: 10.1177/1352458517691149.
    PubMed     Text format     Abstract available


  280. BJORNEVIK K, Chitnis T, Ascherio A, Munger KL, et al
    Polyunsaturated fatty acids and the risk of multiple sclerosis.
    Mult Scler. 2017 Jan 1:1352458517691150. doi: 10.1177/1352458517691150.
    PubMed     Text format     Abstract available


  281. GOPAL S, Mikulskis A, Gold R, Fox RJ, et al
    Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studies.
    Mult Scler. 2017 Jan 1:1352458517690617. doi: 10.1177/1352458517690617.
    PubMed     Text format     Abstract available


  282. MANOUCHEHRINIA A, Westerlind H, Kingwell E, Zhu F, et al
    Age Related Multiple Sclerosis Severity Score: Disability ranked by age.
    Mult Scler. 2017 Jan 1:1352458517690618. doi: 10.1177/1352458517690618.
    PubMed     Text format     Abstract available


  283. DECARD BF, Thone J, Haghikia A, Bornke C, et al
    Listeria rhombencephalitis mimicking a demyelinating event in an immunocompetent young patient.
    Mult Scler. 2017;23:123-125.
    PubMed     Text format     Abstract available


  284. LAROCHELLE C, Metz I, Lecuyer MA, Terouz S, et al
    Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal.
    Mult Scler. 2017;23:72-81.
    PubMed     Text format     Abstract available


  285. BURTON JM, Eliasziw M, Trufyn J, Tung C, et al
    A prospective cohort study of vitamin D in optic neuritis recovery.
    Mult Scler. 2017;23:82-93.
    PubMed     Text format     Abstract available


  286. HAAS J, Schneider K, Schwarz A, Korporal-Kuhnke M, et al
    Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?
    Mult Scler. 2017;23:114-118.
    PubMed     Text format     Abstract available


  287. KALINCIK T, Sormani MP
    Reporting treatment outcomes in observational data: A fine balance.
    Mult Scler. 2017;23:21-22.
    PubMed     Text format     Abstract available


  288. SORMANI MP
    Subgroup analysis in MS trials.
    Mult Scler. 2017;23:34-35.
    PubMed     Text format     Abstract available


    December 2016
  289. MANOUCHEHRINIA A, Beiki O, Hillert J
    Clinical course of multiple sclerosis: A nationwide cohort study.
    Mult Scler. 2016 Dec 12. pii: 1352458516681197.
    PubMed     Text format     Abstract available


  290. BUDHRAM A, Parvathy S, Kremenchutzky M, Silverman M, et al
    Breaking down the gut microbiome composition in multiple sclerosis.
    Mult Scler. 2016 Dec 12. pii: 1352458516682105.
    PubMed     Text format     Abstract available


  291. KAPPOS L, Havrdova E, Giovannoni G, Khatri BO, et al
    No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study.
    Mult Scler. 2016 Dec 1:1352458516683266. doi: 10.1177/1352458516683266.
    PubMed     Text format     Abstract available


  292. CRISTOFANILLI M, Gratch D, Pagano B, McDermott K, et al
    Transglutaminase-6 is an autoantigen in progressive multiple sclerosis and is upregulated in reactive astrocytes.
    Mult Scler. 2016 Dec 1:1352458516684022. doi: 10.1177/1352458516684022.
    PubMed     Text format     Abstract available


  293. WIJNANDS JM, Kingwell E, Zhu F, Zhao Y, et al
    Infection-related health care utilization among people with and without multiple sclerosis.
    Mult Scler. 2016 Dec 1:1352458516681198. doi: 10.1177/1352458516681198.
    PubMed     Text format     Abstract available


  294. IKRAM MA, Vernooij MW, Roshchupkin GV, Hofman A, et al
    Genetic susceptibility to multiple sclerosis: Brain structure and cognitive function in the general population.
    Mult Scler. 2016 Dec 1:1352458516682104. doi: 10.1177/1352458516682104.
    PubMed     Text format     Abstract available


  295. BATISTA S, d'Almeida OC, Afonso A, Freitas S, et al
    Impairment of social cognition in multiple sclerosis: Amygdala atrophy is the main predictor.
    Mult Scler. 2016 Dec 1:1352458516680750. doi: 10.1177/1352458516680750.
    PubMed     Text format     Abstract available


  296. GHEZZI A
    Randomized clinical trials (RCTs) in pediatric multiple sclerosis: Are they really necessary?
    Mult Scler. 2016 Dec 1:1352458516684025. doi: 10.1177/1352458516684025.
    PubMed     Text format    


    November 2016
  297. GOLDMAN MD, Ward MD, Motl RW, Jones DE, et al
    Identification and validation of clinically meaningful benchmarks in the 12-item Multiple Sclerosis Walking Scale.
    Mult Scler. 2016 Nov 30. pii: 1352458516680749.
    PubMed     Text format     Abstract available


  298. HARRISON AM, das Nair R, Moss-Morris R
    Operationalising cognitive fatigability in multiple sclerosis: A Gordian knot that can be cut?
    Mult Scler. 2016 Nov 30. pii: 1352458516681862.
    PubMed     Text format     Abstract available


  299. SEPULVEDA M, Fernandez-Diez B, Martinez-Lapiscina EH, Llufriu S, et al
    Impairment of decision-making in multiple sclerosis: A neuroeconomic approach.
    Mult Scler. 2016 Nov 30. pii: 1352458516682103.
    PubMed     Text format     Abstract available


  300. DEVORAK J, Mokry LE, Morris JA, Forgetta V, et al
    Large differences in adiponectin levels have no clear effect on multiple sclerosis risk: A Mendelian randomization study.
    Mult Scler. 2016 Nov 30. pii: 1352458516681196.
    PubMed     Text format     Abstract available


  301. DATTA G, Violante IR, Scott G, Zimmerman K, et al
    Translocator positron-emission tomography and magnetic resonance spectroscopic imaging of brain glial cell activation in multiple sclerosis.
    Mult Scler. 2016 Nov 30. pii: 1352458516681504.
    PubMed     Text format     Abstract available


  302. VOORTMAN MM, Stojakovic T, Pirpamer L, Jehna M, et al
    Prognostic value of free light chains lambda and kappa in early multiple sclerosis.
    Mult Scler. 2016 Nov 29. pii: 1352458516681503.
    PubMed     Text format     Abstract available


  303. VENTURA RE, Antezana AO, Bacon T, Kister I, et al
    Hispanic Americans and African Americans with multiple sclerosis have more severe disease course than Caucasian Americans.
    Mult Scler. 2016 Nov 29. pii: 1352458516679894.
    PubMed     Text format     Abstract available


  304. ROY S, Frndak S, Drake AS, Irwin L, et al
    Differential effects of aging on motor and cognitive functioning in multiple sclerosis.
    Mult Scler. 2016 Nov 24. pii: 1352458516679036.
    PubMed     Text format     Abstract available


  305. VAN DIJK PA, Kirk-Brown AK, Taylor B, van der Mei I, et al
    Closing the gap: Longitudinal changes in employment for Australians with multiple sclerosis.
    Mult Scler. 2016 Nov 24. pii: 1352458516678934.
    PubMed     Text format     Abstract available


  306. ARROYO GONZALEZ R, Kita M, Crayton H, Havrdova E, et al
    Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis.
    Mult Scler. 2016 Nov 24. pii: 1352458516677589.
    PubMed     Text format     Abstract available


  307. ABDOLLAHPOUR I, Nedjat S, Sahraian MA, Mansournia MA, et al
    Waterpipe smoking associated with multiple sclerosis: A population-based incident case-control study.
    Mult Scler. 2016 Nov 10. pii: 1352458516677867.
    PubMed     Text format     Abstract available


  308. CARLING A, Forsberg A, Gunnarsson M, Nilsagard Y, et al
    CoDuSe group exercise programme improves balance and reduces falls in people with multiple sclerosis: A multi-centre, randomized, controlled pilot study.
    Mult Scler. 2016 Nov 10. pii: 1352458516677591.
    PubMed     Text format     Abstract available


  309. SACCA F, Costabile T, Carotenuto A, Lanzillo R, et al
    The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests.
    Mult Scler. 2016 Nov 3. pii: 1352458516677592.
    PubMed     Text format     Abstract available


  310. MIKOLAJCZAK J, Zimmermann H, Kheirkhah A, Kadas EM, et al
    Patients with multiple sclerosis demonstrate reduced subbasal corneal nerve fibre density.
    Mult Scler. 2016 Nov 3. pii: 1352458516677590.
    PubMed     Text format     Abstract available


  311. CHATAWAY J
    Biotin in progressive multiple sclerosis: A new lead?
    Mult Scler. 2016;22:1640-1641.
    PubMed     Text format    


  312. GABILONDO I, Rilo O, Ojeda N, Pena J, et al
    The influence of posterior visual pathway damage on visual information processing speed in multiple sclerosis.
    Mult Scler. 2016 Nov 1:1352458516676642. doi: 10.1177/1352458516676642.
    PubMed     Text format     Abstract available


  313. CARUANA P, Lemmert K, Ribbons K, Lea R, et al
    Natural killer cell subpopulations are associated with MRI activity in a relapsing-remitting multiple sclerosis patient cohort from Australia.
    Mult Scler. 2016 Nov 1:1352458516679267. doi: 10.1177/1352458516679267.
    PubMed     Text format     Abstract available


    October 2016
  314. PLANCHE V, Ruet A, Coupe P, Lamargue-Hamel D, et al
    Hippocampal microstructural damage correlates with memory impairment in clinically isolated syndrome suggestive of multiple sclerosis.
    Mult Scler. 2016 Oct 25. pii: 1352458516675750.
    PubMed     Text format     Abstract available


  315. BSTEH G, Feige J, Ehling R, Auer M, et al
    Discontinuation of disease-modifying therapies in multiple sclerosis - Clinical outcome and prognostic factors.
    Mult Scler. 2016 Oct 20. pii: 1352458516675751.
    PubMed     Text format     Abstract available


  316. D'AMBROSIO A, Pagani E, Riccitelli GC, Colombo B, et al
    Cerebellar contribution to motor and cognitive performance in multiple sclerosis: An MRI sub-regional volumetric analysis.
    Mult Scler. 2016 Oct 19. pii: 1352458516674567.
    PubMed     Text format     Abstract available


  317. KAVALIUNAS A, Manouchehrinia A, Stawiarz L, Ramanujam R, et al
    Importance of early treatment initiation in the clinical course of multiple sclerosis.
    Mult Scler. 2016 Oct 17. pii: 1352458516675039.
    PubMed     Text format     Abstract available


  318. PIETROBONI AM, Schiano di Cola F, Scarioni M, Fenoglio C, et al
    CSF beta-amyloid as a putative biomarker of disease progression in multiple sclerosis.
    Mult Scler. 2016 Oct 17. pii: 1352458516674566.
    PubMed     Text format     Abstract available


  319. RUANO L, Portaccio E, Goretti B, Niccolai C, et al
    Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes.
    Mult Scler. 2016 Oct 13. pii: 1352458516674367.
    PubMed     Text format     Abstract available


  320. WICKSTROM A, Fagerstrom M, Wickstrom L, Granasen G, et al
    The impact of adjusted work conditions and disease-modifying drugs on work ability in multiple sclerosis.
    Mult Scler. 2016 Oct 6. pii: 1352458516671818.
    PubMed     Text format     Abstract available


  321. AHMAD H, Taylor BV, van der Mei I, Colman S, et al
    The impact of multiple sclerosis severity on health state utility values: Evidence from Australia.
    Mult Scler. 2016 Oct 3. pii: 1352458516672014.
    PubMed     Text format     Abstract available


  322. LUBRINI G, Rios Lago M, Perianez JA, Tallon Barranco A, et al
    The contribution of depressive symptoms to slowness of information processing in relapsing remitting multiple sclerosis.
    Mult Scler. 2016;22:1607-1615.
    PubMed     Text format     Abstract available


  323. ARNETT P
    Lubrini et al.'s study, "The contribution of depressive symptoms to slowness of information processing in relapsing remitting multiple sclerosis".
    Mult Scler. 2016;22:1512-1513.
    PubMed     Text format    


    September 2016
  324. MOBERG JY, Laursen B, Koch-Henriksen N, Thygesen LC, et al
    Employment, disability pension and income for children with parental multiple sclerosis.
    Mult Scler. 2016 Sep 28. pii: 1352458516672016.
    PubMed     Text format     Abstract available


  325. BOESCHOTEN RE, Dekker J, Uitdehaag BM, Beekman AT, et al
    Internet-based treatment for depression in multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2016 Sep 28. pii: 1352458516671820.
    PubMed     Text format     Abstract available


  326. RIBBONS K, Lea R, Tiedeman C, Mackenzie L, et al
    Ongoing increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia: A 50-year study.
    Mult Scler. 2016 Sep 28. pii: 1352458516671819.
    PubMed     Text format     Abstract available


  327. SCHLEMM L, Chien C, Bellmann-Strobl J, Dorr J, et al
    Gadopentetate but not gadobutrol accumulates in the dentate nucleus of multiple sclerosis patients.
    Mult Scler. 2016 Sep 27. pii: 1352458516670738.
    PubMed     Text format     Abstract available


  328. GAFSON A, Craner MJ, Matthews PM
    Personalised medicine for multiple sclerosis care.
    Mult Scler. 2016 Sep 26. pii: 1352458516672017.
    PubMed     Text format     Abstract available


  329. BJORNEVIK K, Riise T, Bostrom I, Casetta L, et al
    Negative interaction between smoking and EBV in the risk of multiple sclerosis: The EnvIMS study.
    Mult Scler. 2016 Sep 23. pii: 1352458516671028.
    PubMed     Text format     Abstract available


  330. COLLIGAN E, Metzler A, Tiryaki E
    Shared decision-making in multiple sclerosis: A review.
    Mult Scler. 2016 Sep 23. pii: 1352458516671204.
    PubMed     Text format     Abstract available


  331. HENGSTMAN GJ
    Controversies in MS: All relapsing multiple sclerosis patients should be managed at a specialist clinic - Combine the best of two worlds!
    Mult Scler. 2016 Sep 21. pii: 1352458516670737.
    PubMed     Text format    


  332. LANDFELDT E, Castelo-Branco A, Svedbom A, Lofroth E, et al
    Sick leave and disability pension before and after diagnosis of multiple sclerosis.
    Mult Scler. 2016 Sep 20. pii: 1352458516667567.
    PubMed     Text format     Abstract available


  333. CHOI IY, Lee P, Hughes AJ, Denney DR, et al
    Longitudinal changes of cerebral glutathione (GSH) levels associated with the clinical course of disease progression in patients with secondary progressive multiple sclerosis.
    Mult Scler. 2016 Sep 12. pii: 1352458516669441.
    PubMed     Text format     Abstract available


  334. ORPEZ-ZAFRA T, Pavia J, Hurtado-Guerrero I, Pinto-Medel MJ, et al
    Decreased soluble IFN-beta receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker.
    Mult Scler. 2016 Sep 9. pii: 1352458516667564.
    PubMed     Text format     Abstract available


  335. HAKOBYAN S, Luppe S, Evans DR, Harding K, et al
    Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder.
    Mult Scler. 2016 Sep 9. pii: 1352458516669002.
    PubMed     Text format     Abstract available


  336. NELSON F, Akhtar MA, Zuniga E, Perez CA, et al
    Novel fMRI working memory paradigm accurately detects cognitive impairment in multiple sclerosis.
    Mult Scler. 2016 Sep 9. pii: 1352458516666186.
    PubMed     Text format     Abstract available


  337. GRYTTEN N, Skar AB, Aarseth JH, Assmus J, et al
    The influence of coping styles on long-term employment in multiple sclerosis: A prospective study.
    Mult Scler. 2016 Sep 6. pii: 1352458516667240.
    PubMed     Text format     Abstract available


  338. TOURBAH A, Lebrun-Frenay C, Edan G, Clanet M, et al
    MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study.
    Mult Scler. 2016 Sep 1. pii: 1352458516667568.
    PubMed     Text format     Abstract available


  339. MUKHOPADHYAY S, Fellows K, Browne RW, Khare P, et al
    Interdependence of oxysterols with cholesterol profiles in multiple sclerosis.
    Mult Scler. 2016 Sep 1. pii: 1352458516666187.
    PubMed     Text format     Abstract available


    August 2016
  340. TROJAN DA, Cybulsky AV
    Drinking away fatigue in multiple sclerosis.
    Mult Scler. 2016 Aug 19. pii: 1352458516666337.
    PubMed     Text format    


  341. CINCOTTA MC, Engelhard MM, Stankey M, Goldman MD, et al
    Fatigue and fluid hydration status in multiple sclerosis: A hypothesis.
    Mult Scler. 2016 Aug 19. pii: 1352458516663854.
    PubMed     Text format     Abstract available


  342. MATHIAS A, Perriard G, Canales M, Soneson C, et al
    Increased ex vivo antigen presentation profile of B cells in multiple sclerosis.
    Mult Scler. 2016 Aug 8. pii: 1352458516664210.
    PubMed     Text format     Abstract available


  343. LANZA G, Ferri R, Bella R, Ferini-Strambi L, et al
    The impact of drugs for multiple sclerosis on sleep.
    Mult Scler. 2016 Aug 8. pii: 1352458516664034.
    PubMed     Text format     Abstract available


  344. KHAN O, Rieckmann P, Boyko A, Selmaj K, et al
    Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study.
    Mult Scler. 2016 Aug 8. pii: 1352458516664033.
    PubMed     Text format     Abstract available


  345. KIM HJ, Lee J
    Response to letter regarding article 'Comparison of myelin water fraction values in periventricular white matter lesions between multiple sclerosis and neuromyelitis optica spectrum disorder'.
    Mult Scler. 2016 Aug 5. pii: 1352458516662730.
    PubMed     Text format    


  346. POMPA A, Morone G, Iosa M, Pace L, et al
    Does robot-assisted gait training improve ambulation in highly disabled multiple sclerosis people? A pilot randomized control trial.
    Mult Scler. 2016 Aug 2. pii: 1352458516663033.
    PubMed     Text format     Abstract available


  347. KALINCIK T, Kuhle J, Pucci E, Rojas JI, et al
    Data quality evaluation for observational multiple sclerosis registries.
    Mult Scler. 2016 Aug 1. pii: 1352458516662728.
    PubMed     Text format     Abstract available


  348. BOUTIERE C, Rey C, Zaaraoui W, Le Troter A, et al
    Improvement of spasticity following intermittent theta burst stimulation in multiple sclerosis is associated with modulation of resting-state functional connectivity of the primary motor cortices.
    Mult Scler. 2016 Aug 1. pii: 1352458516661640.
    PubMed     Text format     Abstract available


  349. KHOURY SJ, Rochon J, Ding L, Byron M, et al
    ACCLAIM: A randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple sclerosis.
    Mult Scler. 2016 Aug 1. pii: 1352458516662727.
    PubMed     Text format     Abstract available


  350. SCHREIBER K, Magyari M, Sellebjerg F, Iversen P, et al
    High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial.
    Mult Scler. 2016 Aug 1. pii: 1352458516661048.
    PubMed     Text format     Abstract available


  351. GROSS CC, Schulte-Mecklenbeck A, Hanning U, Posevitz-Fejfar A, et al
    Distinct pattern of lesion distribution in multiple sclerosis is associated with different circulating T-helper and helper-like innate lymphoid cell subsets.
    Mult Scler. 2016 Aug 1. pii: 1352458516662726.
    PubMed     Text format     Abstract available


  352. VERMERSCH P, Smets L, Gold R
    Conclusions: Calls to action for improving the life of MS patients and their families.
    Mult Scler. 2016;22.
    PubMed     Text format     Abstract available


  353. VERMERSCH P, Faller A, Czarnota-Szalkowska D, Meesen B, et al
    The patient's perspective: How to create awareness for improving access to care and treatment of MS patients?
    Mult Scler. 2016;22.
    PubMed     Text format     Abstract available


    July 2016
  354. BUHLER U, Fleischer V, Luessi F, Rezk A, et al
    Role of IL-17-producing lymphocytes in severity of multiple sclerosis upon natalizumab treatment.
    Mult Scler. 2016 Jul 19. pii: 1352458516658559.
    PubMed     Text format     Abstract available


  355. ONTANEDA D, Love TE
    Propensity methods for multiple sclerosis: The devil is in the details.
    Mult Scler. 2016 Jul 13. pii: 1352458516660390.
    PubMed     Text format    


  356. SBARDELLA E, Upadhyay N, Tona F, Prosperini L, et al
    Dentate nucleus connectivity in adult patients with multiple sclerosis: functional changes at rest and correlation with clinical features.
    Mult Scler. 2016 Jul 13. pii: 1352458516657438.
    PubMed     Text format     Abstract available


    June 2016
  357. COFRE LIZAMA LE, Khan F, Lee PV, Galea MP, et al
    The use of laboratory gait analysis for understanding gait deterioration in people with multiple sclerosis.
    Mult Scler. 2016 Jun 30. pii: 1352458516658137.
    PubMed     Text format     Abstract available


  358. SOELBERG SORENSEN P, Sellebjerg F
    Neurofilament in CSF-A biomarker of disease activity and long-term prognosis in multiple sclerosis.
    Mult Scler. 2016 Jun 30. pii: 1352458516658560.
    PubMed     Text format    


  359. MCKAY KA, Tremlett H, Patten SB, Fisk JD, et al
    Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study.
    Mult Scler. 2016 Jun 29. pii: 1352458516657440.
    PubMed     Text format     Abstract available


  360. VACCHI L, Rocca MA, Meani A, Rodegher M, et al
    Working memory network dysfunction in relapse-onset multiple sclerosis phenotypes: A clinical-imaging evaluation.
    Mult Scler. 2016 Jun 28. pii: 1352458516656809.
    PubMed     Text format     Abstract available


  361. NISHIHARA H, Shimizu F, Kitagawa T, Yamanaka N, et al
    Identification of galectin-3 as a possible antibody target for secondary progressive multiple sclerosis.
    Mult Scler. 2016 Jun 23. pii: 1352458516655217.
    PubMed     Text format     Abstract available


  362. SETHI V, Nair G, Absinta M, Sati P, et al
    Slowly eroding lesions in multiple sclerosis.
    Mult Scler. 2016 Jun 23. pii: 1352458516655403.
    PubMed     Text format     Abstract available


  363. ROSJO E, Lossius A, Abdelmagid N, Lindstrom JC, et al
    Effect of high-dose vitamin D3 supplementation on antibody responses against Epstein-Barr virus in relapsing-remitting multiple sclerosis.
    Mult Scler. 2016 Jun 20. pii: 1352458516654310.
    PubMed     Text format     Abstract available


  364. MENON S, Zhu F, Shirani A, Oger J, et al
    Disability progression in aggressive multiple sclerosis.
    Mult Scler. 2016 Jun 20. pii: 1352458516653273.
    PubMed     Text format     Abstract available


  365. NAISMITH RT
    Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy-NO.
    Mult Scler. 2016 Jun 8. pii: 1352458516644676.
    PubMed     Text format    


  366. MILLER AE
    Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy-Commentary.
    Mult Scler. 2016 Jun 8. pii: 1352458516649039.
    PubMed     Text format    


  367. GIOVANNONI G
    Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy-YES.
    Mult Scler. 2016 Jun 8. pii: 1352458516650737.
    PubMed     Text format    


  368. BUSCARINU MC, Cerasoli B, Annibali V, Policano C, et al
    Altered intestinal permeability in patients with relapsing-remitting multiple sclerosis: A pilot study.
    Mult Scler. 2016 Jun 6. pii: 1352458516652498.
    PubMed     Text format     Abstract available


  369. CALABRESE M, Castellaro M, Bertoldo A, De Luca A, et al
    Epilepsy in multiple sclerosis: The role of temporal lobe damage.
    Mult Scler. 2016 Jun 3. pii: 1352458516651502.
    PubMed     Text format     Abstract available


    May 2016
  370. FLEISCHER V, Groger A, Koirala N, Droby A, et al
    Increased structural white and grey matter network connectivity compensates for functional decline in early multiple sclerosis.
    Mult Scler. 2016 May 31. pii: 1352458516651503.
    PubMed     Text format     Abstract available


  371. LEE H, Narayanan S, Brown RA, Chen JT, et al
    Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis.
    Mult Scler. 2016 May 31. pii: 1352458516650992.
    PubMed     Text format     Abstract available


  372. VISTBAKKA J, Elovaara I, Lehtimaki T, Hagman S, et al
    Circulating microRNAs as biomarkers in progressive multiple sclerosis.
    Mult Scler. 2016 May 31. pii: 1352458516651141.
    PubMed     Text format     Abstract available


  373. CONWAY DS, Thompson NR, Cohen JA
    Influence of hypertension, diabetes, hyperlipidemia, and obstructive lung disease on multiple sclerosis disease course.
    Mult Scler. 2016 May 26. pii: 1352458516650512.
    PubMed     Text format     Abstract available


  374. BARONCINI D, Ghezzi A, Annovazzi PO, Colombo B, et al
    Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
    Mult Scler. 2016 May 26. pii: 1352458516650736.
    PubMed     Text format     Abstract available


  375. UHER T, Havrdova E, Sobisek L, Krasensky J, et al
    Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?
    Mult Scler. 2016 May 26. pii: 1352458516650525.
    PubMed     Text format     Abstract available


  376. OTERO-ROMERO S, Sastre-Garriga J, Comi G, Hartung HP, et al
    Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper.
    Mult Scler. 2016 May 19. pii: 1352458516643600.
    PubMed     Text format     Abstract available


  377. LIU G, Zhang F, Jiang Y, Hu Y, et al
    Integrating genome-wide association studies and gene expression data highlights dysregulated multiple sclerosis risk pathways.
    Mult Scler. 2016 May 19. pii: 1352458516649038.
    PubMed     Text format     Abstract available


  378. GOLD R, Arnold DL, Bar-Or A, Hutchinson M, et al
    Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study.
    Mult Scler. 2016 May 19. pii: 1352458516649037.
    PubMed     Text format     Abstract available


  379. COSTA SL, Genova HM, DeLuca J, Chiaravalloti ND, et al
    Information processing speed in multiple sclerosis: Past, present, and future.
    Mult Scler. 2016 May 9. pii: 1352458516645869.
    PubMed     Text format     Abstract available


  380. BJORNEVIK K, Riise T, Benjaminsen E, Celius EG, et al
    Level of education and multiple sclerosis risk over a 50-year period: Registry-based sibling study.
    Mult Scler. 2016 May 5. pii: 1352458516646863.
    PubMed     Text format     Abstract available


  381. MILLER AE
    Multiple sclerosis disease-modifying therapy and pregnancy.
    Mult Scler. 2016;22:715-6.
    PubMed     Text format    


    April 2016
  382. PAPATHEMELI D, Grafe R, Hildebrandt U, Zettl UK, et al
    Development of a primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma during treatment of multiple sclerosis with fingolimod.
    Mult Scler. 2016 Apr 26. pii: 1352458516645868.
    PubMed     Text format     Abstract available


  383. HUTCHINSON M
    All relapsing multiple sclerosis patients should be managed at a specialist clinic - Commentary.
    Mult Scler. 2016 Apr 22. pii: 1352458516646466.
    PubMed     Text format    


  384. BRENNER R
    All relapsing multiple sclerosis patients should be seen in specialist clinics - NO.
    Mult Scler. 2016 Apr 22. pii: 1352458516642855.
    PubMed     Text format    


  385. BROWNLEE WJ, Ciccarelli O
    All relapsing multiple sclerosis patients should be managed at a specialist clinic - YES.
    Mult Scler. 2016 Apr 22. pii: 1352458516636474.
    PubMed     Text format    


  386. LUDWIN SK, Rao VT, Moore CS, Antel JP, et al
    Astrocytes in multiple sclerosis.
    Mult Scler. 2016 Apr 19. pii: 1352458516643396.
    PubMed     Text format     Abstract available


  387. SASTRE-GARRIGA J
    Leptomeningeal enhancement in Susac's syndrome and multiple sclerosis: Time to expect the unexpected?
    Mult Scler. 2016 Apr 18. pii: 1352458516644677.
    PubMed     Text format     Abstract available


  388. VELDHUIJZEN VAN ZANTEN JJ, Pilutti LA, Duda JL, Motl RW, et al
    Sedentary behaviour in people with multiple sclerosis: Is it time to stand up against MS?
    Mult Scler. 2016 Apr 12. pii: 1352458516644340.
    PubMed     Text format     Abstract available


  389. WESTERLIND H, Stawiarz L, Fink K, Hillert J, et al
    A significant decrease in diagnosis of primary progressive multiple sclerosis: A cohort study.
    Mult Scler. 2016 Apr 12. pii: 1352458516643394.
    PubMed     Text format     Abstract available


  390. BEAUCHEMINA P, Carruthers R
    Response to: Tocilizumab, neuromyelitis optica (NMO), and multiple sclerosis.
    Mult Scler. 2016 Apr 11. pii: 1352458516643398.
    PubMed     Text format    


  391. KOCH-HENRIKSEN N, Magyari M, Sellebjerg F, Soelberg Sorensen P, et al
    A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod.
    Mult Scler. 2016 Apr 7. pii: 1352458516643393.
    PubMed     Text format     Abstract available


  392. STEWART T, Spelman T, Havrdova E, Horakova D, et al
    Contribution of different relapse phenotypes to disability in multiple sclerosis.
    Mult Scler. 2016 Apr 7. pii: 1352458516643392.
    PubMed     Text format     Abstract available


  393. SEEBACHER B, Kuisma R, Glynn A, Berger T, et al
    The effect of rhythmic-cued motor imagery on walking, fatigue and quality of life in people with multiple sclerosis: A randomised controlled trial.
    Mult Scler. 2016 Apr 7. pii: 1352458516644058.
    PubMed     Text format     Abstract available


  394. UHER T, Vaneckova M, Sobisek L, Tyblova M, et al
    Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis.
    Mult Scler. 2016 Apr 6. pii: 1352458516642314.
    PubMed     Text format     Abstract available


  395. MATOULA T, Nikolaou V, Marinos L, Katsavos S, et al
    Lymphomatoid papulosis type D in a fingolimod-treated multiple sclerosis patient.
    Mult Scler. 2016 Apr 6. pii: 1352458516642032.
    PubMed     Text format    


  396. HARDY TA, Tobin WO, Lucchinetti CF
    Exploring the overlap between multiple sclerosis, tumefactive demyelination and Balo's concentric sclerosis.
    Mult Scler. 2016 Apr 1. pii: 1352458516641776.
    PubMed     Text format     Abstract available


  397. HANKEN K, Eling P, Hildebrandt H
    Is there a cognitive signature for MS-related fatigue? Response to Feinstein.
    Mult Scler. 2016;22:575-6.
    PubMed     Text format    


  398. RACCA V, Di Rienzo M, Cavarretta R, Toccafondi A, et al
    Response to letter regarding article 'Fingolimod effects on left ventricular function in multiple sclerosis'.
    Mult Scler. 2016;22:708-9.
    PubMed     Text format    


  399. MODVIG S, Degn M, Sander B, Horwitz H, et al
    Cerebrospinal fluid neurofilament light chain levels predict visual outcome after optic neuritis.
    Mult Scler. 2016;22:590-8.
    PubMed     Text format     Abstract available


  400. HADHOUM N, Hodel J, Defoort-Dhellemmes S, Duhamel A, et al
    Length of optic nerve double inversion recovery hypersignal is associated with retinal axonal loss.
    Mult Scler. 2016;22:649-58.
    PubMed     Text format     Abstract available


  401. NEMECEK A, Zimmermann H, Rubenthaler J, Fleischer V, et al
    Flow cytometric analysis of T cell/monocyte ratio in clinically isolated syndrome identifies patients at risk of rapid disease progression.
    Mult Scler. 2016;22:483-93.
    PubMed     Text format     Abstract available


    March 2016
  402. PATEL VP, Zambrana A, Walker LA, Herrmann N, et al
    Distraction adds to the cognitive burden in multiple sclerosis.
    Mult Scler. 2016 Mar 24. pii: 1352458516641208.
    PubMed     Text format     Abstract available


  403. STROHM T, Chaudhry B, Willis MA, Shook S, et al
    Reversible cerebral vasoconstriction syndrome associated with interferon beta-1a use for multiple sclerosis.
    Mult Scler. 2016 Mar 24. pii: 1352458516641774.
    PubMed     Text format     Abstract available


  404. CADAVID D, Cohen JA, Freedman MS, Goldman MD, et al
    The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.
    Mult Scler. 2016 Mar 22. pii: 1352458516638941.
    PubMed     Text format     Abstract available


  405. NOVAKOVA L, Axelsson M, Khademi M, Zetterberg H, et al
    Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis.
    Mult Scler. 2016 Mar 21. pii: 1352458516639384.
    PubMed     Text format     Abstract available


  406. MIDAGLIA L, Juega Marino JM, Sastre-Garriga J, Rovira A, et al
    An uncommon first manifestation of multiple sclerosis: Tako-Tsubo cardiomyopathy.
    Mult Scler. 2016 Mar 18. pii: 1352458516638557.
    PubMed     Text format     Abstract available


  407. HILZ MJ
    Cardiac stunning as first manifestation of multiple sclerosis: A case report reminding us not to overlook cardiovascular autonomic dysfunction in multiple sclerosis.
    Mult Scler. 2016 Mar 18. pii: 1352458516638559.
    PubMed     Text format     Abstract available


  408. BECKER J, Rolfs A, Karabul N, Berlit P, et al
    D313Y mutation in the differential diagnosis of white matter lesions: Experiences from a multiple sclerosis outpatient clinic.
    Mult Scler. 2016 Mar 18. pii: 1352458516638747.
    PubMed     Text format     Abstract available


  409. PETRACCA M, Cordano C, Cellerino M, Button J, et al
    Retinal degeneration in primary-progressive multiple sclerosis: A role for cortical lesions?
    Mult Scler. 2016 Mar 18. pii: 1352458516637679.
    PubMed     Text format     Abstract available


  410. ALBOR C, du Sautoy T, Kali Vanan N, Turner BP, et al
    Ethnicity and prevalence of multiple sclerosis in east London.
    Mult Scler. 2016 Mar 17. pii: 1352458516638746.
    PubMed     Text format     Abstract available


  411. OBERMANN M, Ruck T, Pfeuffer S, Baum J, et al
    Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis.
    Mult Scler. 2016 Mar 15. pii: 1352458516638558.
    PubMed     Text format     Abstract available


  412. ZINGER A, Latham SL, Combes V, Byrne S, et al
    Plasma levels of endothelial and B-cell-derived microparticles are restored by fingolimod treatment in multiple sclerosis patients.
    Mult Scler. 2016 Mar 1. pii: 1352458516636959.
    PubMed     Text format     Abstract available


  413. BEVER CT JR, Wallin MT
    Tribute to John F. Kurtzke, MD, FACP, FAAN: 1926-2015.
    Mult Scler. 2016;22:267-8.
    PubMed     Text format    


  414. ENZINGER C, Pinter D, Rocca MA, De Luca J, et al
    Longitudinal fMRI studies: Exploring brain plasticity and repair in MS.
    Mult Scler. 2016;22:269-78.
    PubMed     Text format     Abstract available


  415. PEKCEVIK Y, Mitchell CH, Mealy MA, Orman G, et al
    Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging.
    Mult Scler. 2016;22:302-11.
    PubMed     Text format     Abstract available


  416. MAKHANI N, Banwell B, Tellier R, Yea C, et al
    Viral exposures and MS outcome in a prospective cohort of children with acquired demyelination.
    Mult Scler. 2016;22:385-8.
    PubMed     Text format     Abstract available


  417. VAN SCHEPENDOM J, Gielen J, Laton J, Nagels G, et al
    Assessing PML risk under immunotherapy: if all you have is a hammer, everything looks like a nail.
    Mult Scler. 2016;22:389-92.
    PubMed     Text format     Abstract available


    February 2016
  418. THIEL S, Langer-Gould A, Rockhoff M, Haghikia A, et al
    Interferon-beta exposure during first trimester is safe in women with multiple sclerosis-A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry.
    Mult Scler. 2016 Feb 26. pii: 1352458516634872.
    PubMed     Text format     Abstract available


  419. D'AMICO E, Leone C, Hayrettin T, Patti F, et al
    Can we define a rehabilitation strategy for cognitive impairment in progressive multiple sclerosis? A critical appraisal.
    Mult Scler. 2016 Feb 26. pii: 1352458516632066.
    PubMed     Text format     Abstract available


  420. KIM SH, Kwak K, Jeong IH, Hyun JW, et al
    Cognitive impairment differs between neuromyelitis optica spectrum disorder and multiple sclerosis.
    Mult Scler. 2016 Feb 26. pii: 1352458516636246.
    PubMed     Text format     Abstract available


  421. FIEST KM, Marrie RA, Jette N, Bennett DA, et al
    The Standards of Reporting of Neurological Disorders (STROND) checklist: Application to multiple sclerosis.
    Mult Scler. 2016 Feb 26. pii: 1352458516634873.
    PubMed     Text format     Abstract available


  422. SUMOWSKI JF, Rocca MA, Leavitt VM, Riccitelli G, et al
    Reading, writing, and reserve: Literacy activities are linked to hippocampal volume and memory in multiple sclerosis.
    Mult Scler. 2016 Feb 26. pii: 1352458516630822.
    PubMed     Text format     Abstract available


  423. WANG Y, Bos SD, Harbo HF, Thompson WK, et al
    Genetic overlap between multiple sclerosis and several cardiovascular disease risk factors.
    Mult Scler. 2016 Feb 26. pii: 1352458516635873.
    PubMed     Text format     Abstract available


  424. JEONG IH, Choi JY, Kim SH, Hyun JW, et al
    Comparison of myelin water fraction values in periventricular white matter lesions between multiple sclerosis and neuromyelitis optica spectrum disorder.
    Mult Scler. 2016 Feb 26. pii: 1352458516636247.
    PubMed     Text format     Abstract available


  425. CAVALLARI M, Palotai M, Glanz BI, Egorova S, et al
    Fatigue predicts disease worsening in relapsing-remitting multiple sclerosis patients.
    Mult Scler. 2016 Feb 26. pii: 1352458516635874.
    PubMed     Text format     Abstract available


  426. RAZAZ N, Tremlett H, Marrie RA, Joseph KS, et al
    Peripartum depression in parents with multiple sclerosis and psychiatric disorders in children.
    Mult Scler. 2016 Feb 22. pii: 1352458516631037.
    PubMed     Text format     Abstract available


  427. JIANG H, Delgado S, Tan J, Liu C, et al
    Impaired retinal microcirculation in multiple sclerosis.
    Mult Scler. 2016 Feb 22. pii: 1352458516631035.
    PubMed     Text format     Abstract available


  428. SANAI SA, Saini V, Benedict RH, Zivadinov R, et al
    Aging and multiple sclerosis.
    Mult Scler. 2016 Feb 19. pii: 1352458516634871.
    PubMed     Text format     Abstract available


  429. PHE V, Pakzad M, Curtis C, Porter B, et al
    Urinary tract infections in multiple sclerosis.
    Mult Scler. 2016 Feb 18. pii: 1352458516633903.
    PubMed     Text format     Abstract available


  430. DECKER Y, Schomburg R, Nemeth E, Vitkin A, et al
    Abnormal galactosylation of immunoglobulin G in cerebrospinal fluid of multiple sclerosis patients.
    Mult Scler. 2016 Feb 16. pii: 1352458516631036.
    PubMed     Text format     Abstract available


  431. MOKKINK LB, Galindo-Garre F, Uitdehaag BM
    Evaluation of the Multiple Sclerosis Walking Scale-12 (MSWS-12) in a Dutch sample: Application of item response theory.
    Mult Scler. 2016 Feb 12. pii: 1352458516630821.
    PubMed     Text format     Abstract available


  432. SCALFARI A, Lederer C, Daumer M, Nicholas R, et al
    The relationship of age with the clinical phenotype in multiple sclerosis.
    Mult Scler. 2016 Feb 11. pii: 1352458516630396.
    PubMed     Text format     Abstract available


  433. PASTO L, Portaccio E, Goretti B, Ghezzi A, et al
    The cognitive reserve theory in the setting of pediatric-onset multiple sclerosis.
    Mult Scler. 2016 Feb 11. pii: 1352458516629559.
    PubMed     Text format     Abstract available


  434. JARIUS S, Metz I, Konig FB, Ruprecht K, et al
    Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in 'pattern II multiple sclerosis' and brain biopsy findings in a MOG-IgG-positive case.
    Mult Scler. 2016 Feb 11. pii: 1352458515622986.
    PubMed     Text format     Abstract available


  435. PAKPOOR J, Wotton CJ, Schmierer K, Giovannoni G, et al
    Gender identity disorders and multiple sclerosis risk: A national record-linkage study.
    Mult Scler. 2016 Feb 8. pii: 1352458515627205.
    PubMed     Text format     Abstract available


  436. BISECCO A, Caiazzo G, d'Ambrosio A, Sacco R, et al
    Fatigue in multiple sclerosis: The contribution of occult white matter damage.
    Mult Scler. 2016 Feb 4. pii: 1352458516628331.
    PubMed     Text format     Abstract available


  437. PRAVATA E, Zecca C, Sestieri C, Caulo M, et al
    Hyperconnectivity of the dorsolateral prefrontal cortex following mental effort in multiple sclerosis patients with cognitive fatigue.
    Mult Scler. 2016 Feb 4. pii: 1352458515625806.
    PubMed     Text format     Abstract available


  438. FAIVRE A, Robinet E, Guye M, Rousseau C, et al
    Depletion of brain functional connectivity enhancement leads to disability progression in multiple sclerosis: A longitudinal resting-state fMRI study.
    Mult Scler. 2016 Feb 2. pii: 1352458516628657.
    PubMed     Text format     Abstract available


  439. TAYLOR BV
    Modeling the course and outcomes of multiple sclerosis is statistical twaddle-Yes.
    Mult Scler. 2016;22:140-2.
    PubMed     Text format    


  440. BERGAMASCHI R, Montomoli C
    Modeling the course and outcomes of MS is statistical twaddle--No.
    Mult Scler. 2016;22:142-4.
    PubMed     Text format    


  441. BEAUCHEMIN P, Carruthers R
    MS arising during Tocilizumab therapy for rheumatoid arthritis.
    Mult Scler. 2016;22:254-6.
    PubMed     Text format     Abstract available


  442. FERNANDEZ-CARBONELL C, Vargas-Lowy D, Musallam A, Healy B, et al
    Clinical and MRI phenotype of children with MOG antibodies.
    Mult Scler. 2016;22:174-84.
    PubMed     Text format     Abstract available


  443. HUPPERTS R, Lycke J, Short C, Gasperini C, et al
    Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial.
    Mult Scler. 2016;22:212-21.
    PubMed     Text format     Abstract available


    January 2016
  444. LAULE C, Yung A, Pavolva V, Bohnet B, et al
    High-resolution myelin water imaging in post-mortem multiple sclerosis spinal cord: A case report.
    Mult Scler. 2016 Jan 27. pii: 1352458515624559.
    PubMed     Text format     Abstract available


  445. ZHOU Y, Zhu G, Charlesworth JC, Simpson S Jr, et al
    Genetic loci for Epstein-Barr virus nuclear antigen-1 are associated with risk of multiple sclerosis.
    Mult Scler. 2016 Jan 27. pii: 1352458515626598.
    PubMed     Text format     Abstract available


  446. BEHRENS JR, Mertens S, Kruger T, Grobelny A, et al
    Validity of visual perceptive computing for static posturography in patients with multiple sclerosis.
    Mult Scler. 2016 Jan 26. pii: 1352458515625807.
    PubMed     Text format     Abstract available


  447. GEORGE IC, Sati P, Absinta M, Cortese IC, et al
    Clinical 3-tesla FLAIR* MRI improves diagnostic accuracy in multiple sclerosis.
    Mult Scler. 2016 Jan 14. pii: 1352458515624975.
    PubMed     Text format     Abstract available


  448. ZORNER B, Filli L, Reuter K, Kapitza S, et al
    Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern.
    Mult Scler. 2016 Jan 13. pii: 1352458515622695.
    PubMed     Text format     Abstract available


  449. KHALIL M, Renner A, Langkammer C, Enzinger C, et al
    Cerebrospinal fluid lipocalin 2 in patients with clinically isolated syndromes and early multiple sclerosis.
    Mult Scler. 2016 Jan 13. pii: 1352458515624560.
    PubMed     Text format     Abstract available


  450. OHRFELT A, Axelsson M, Malmestrom C, Novakova L, et al
    Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone.
    Mult Scler. 2016 Jan 11. pii: 1352458515624558.
    PubMed     Text format     Abstract available


  451. PANDIT L, Ban M, Beecham AH, McCauley JL, et al
    European multiple sclerosis risk variants in the south Asian population.
    Mult Scler. 2016 Jan 11. pii: 1352458515624270.
    PubMed     Text format     Abstract available


  452. BHARGAVA P, Calabresi PA
    Metabolomics in multiple sclerosis.
    Mult Scler. 2016 Jan 11. pii: 1352458515622827.
    PubMed     Text format     Abstract available


  453. HOJJAT SP, Cantrell CG, Vitorino R, Feinstein A, et al
    Regional reduction in cortical blood flow among cognitively impaired adults with relapsing-remitting multiple sclerosis patients.
    Mult Scler. 2016 Jan 11. pii: 1352458515622696.
    PubMed     Text format     Abstract available


  454. NIELSEN NM, Harpsoe MC, Simonsen J, Stenager E, et al
    Self-rated health in women prior to clinical onset of multiple sclerosis: A study within the Danish National Birth Cohort.
    Mult Scler. 2016 Jan 8. pii: 1352458515621623.
    PubMed     Text format     Abstract available


  455. HASSELMANN H, Bellmann-Strobl J, Ricken R, Oberwahrenbrock T, et al
    Characterizing the phenotype of multiple sclerosis-associated depression in comparison with idiopathic major depression.
    Mult Scler. 2016 Jan 8. pii: 1352458515622826.
    PubMed     Text format     Abstract available


  456. COMABELLA M
    Tocilizumab and multiple sclerosis: a causal relationship? Clinical Commentary on the case report entitled - MS arising during Tocilizumab therapy for rheumatoid arthritis.
    Mult Scler. 2016 Jan 7. pii: 1352458515623863.
    PubMed     Text format     Abstract available


  457. MEIJER KA, Muhlert N, Cercignani M, Sethi V, et al
    White matter tract abnormalities are associated with cognitive dysfunction in secondary progressive multiple sclerosis.
    Mult Scler. 2016 Jan 5. pii: 1352458515622694.
    PubMed     Text format     Abstract available


  458. MORI F, Nistico R, Nicoletti CG, Zagaglia S, et al
    RANTES correlates with inflammatory activity and synaptic excitability in multiple sclerosis.
    Mult Scler. 2016 Jan 5. pii: 1352458515621796.
    PubMed     Text format     Abstract available


  459. SASTRE-GARRIGA J, Wiendl H
    Highlights from the 31st ECTRIMS congress - Barcelona 2015.
    Mult Scler. 2016;22:7-10.
    PubMed     Text format    


  460. REINGOLD SC, Lublin FD
    William Austin Sibley, MD (1925-2015).
    Mult Scler. 2016;22:11-2.
    PubMed     Text format    


  461. FREEDMAN MS
    Are we in need of NEDA?
    Mult Scler. 2016;22:5-6.
    PubMed     Text format    


  462. ZAJDA M, Kazmierczak B, Zakrzewska-Pniewska B
    Aquaporin-4: A novel diagnostic biomarker for seronegative neuromyelitis optica.
    Mult Scler. 2016;22:125-6.
    PubMed     Text format    


    December 2015
  463. RAZAZ N, Joseph KS, Boyce WT, Guhn M, et al
    Children of chronically ill parents: Relationship between parental multiple sclerosis and childhood developmental health.
    Mult Scler. 2015 Dec 18. pii: 1352458515621624.
    PubMed     Text format     Abstract available


  464. JONKMAN LE, Fleysher L, Steenwijk MD, Koeleman JA, et al
    Ultra-high field MTR and qR2* differentiates subpial cortical lesions from normal-appearing gray matter in multiple sclerosis.
    Mult Scler. 2015 Dec 16. pii: 1352458515620499.
    PubMed     Text format     Abstract available


  465. CONTE A, Li Voti P, Pontecorvo S, Quartuccio ME, et al
    Attention-related changes in short-term cortical plasticity help to explain fatigue in multiple sclerosis.
    Mult Scler. 2015 Dec 16. pii: 1352458515619780.
    PubMed     Text format     Abstract available


  466. STRAUDI S, Fanciullacci C, Martinuzzi C, Pavarelli C, et al
    The effects of robot-assisted gait training in progressive multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2015 Dec 10. pii: 1352458515620933.
    PubMed     Text format     Abstract available


  467. MISTRY N, Abdel-Fahim R, Samaraweera A, Mougin O, et al
    Imaging central veins in brain lesions with 3-T T2*-weighted magnetic resonance imaging differentiates multiple sclerosis from microangiopathic brain lesions.
    Mult Scler. 2015 Dec 10. pii: 1352458515616700.
    PubMed     Text format     Abstract available


    November 2015
  468. SCHEEPE JR, Wong YY, van Pelt ED, Ketelslegers IA, et al
    Neurogenic lower urinary tract dysfunction in the early disease phase of paediatric multiple sclerosis.
    Mult Scler. 2015 Nov 20. pii: 1352458515618541.
    PubMed     Text format     Abstract available


  469. KAPPOS L, De Stefano N, Freedman MS, Cree BA, et al
    Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.
    Mult Scler. 2015 Nov 19. pii: 1352458515616701.
    PubMed     Text format     Abstract available


  470. STEENWIJK MD, Vrenken H, Jonkman LE, Daams M, et al
    High-resolution T1-relaxation time mapping displays subtle, clinically relevant, gray matter damage in long-standing multiple sclerosis.
    Mult Scler. 2015 Nov 12. pii: 1352458515615953.
    PubMed     Text format     Abstract available


  471. FOK A, Williams T, McLean CA, Butler E, et al
    Interferon beta-1a long-term therapy related to pulmonary arterial hypertension in multiple sclerosis patients.
    Mult Scler. 2015 Nov 12. pii: 1352458515618020.
    PubMed     Text format     Abstract available


  472. YAMASAKI R, Matsushita T, Fukazawa T, Yokoyama K, et al
    Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica.
    Mult Scler. 2015 Nov 12. pii: 1352458515617248.
    PubMed     Text format     Abstract available


  473. WATTJES MP, Wijburg MT, Vennegoor A, Witte BI, et al
    Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.
    Mult Scler. 2015 Nov 12. pii: 1352458515615225.
    PubMed     Text format     Abstract available


  474. HUTCHINSON M
    Neurodegeneration in multiple sclerosis is a process separate from inflammation: No.
    Mult Scler. 2015;21:1628-31.
    PubMed     Text format    


  475. LOUAPRE C, Lubetzki C
    Neurodegeneration in multiple sclerosis is a process separate from inflammation: Yes.
    Mult Scler. 2015;21:1626-8.
    PubMed     Text format    


    October 2015
  476. WILLIS MD, Harding KE, Pickersgill TP, Wardle M, et al
    Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort.
    Mult Scler. 2015 Oct 29. pii: 1352458515614092.
    PubMed     Text format     Abstract available


  477. UDDIN MN, Lebel RM, Seres P, Blevins G, et al
    Spin echo transverse relaxation and atrophy in multiple sclerosis deep gray matter: A two-year longitudinal study.
    Mult Scler. 2015 Oct 26. pii: 1352458515614091.
    PubMed     Text format     Abstract available


  478. AHLBRECHT J, Martino F, Pul R, Skripuletz T, et al
    Deregulation of microRNA-181c in cerebrospinal fluid of patients with clinically isolated syndrome is associated with early conversion to relapsing-remitting multiple sclerosis.
    Mult Scler. 2015 Oct 22. pii: 1352458515613641.
    PubMed     Text format     Abstract available


  479. ROCCA MA, Meani A, Riccitelli GC, Colombo B, et al
    Abnormal adaptation over time of motor network recruitment in multiple sclerosis patients with fatigue.
    Mult Scler. 2015 Oct 22. pii: 1352458515614407.
    PubMed     Text format     Abstract available


  480. HEITMANN H, Biberacher V, Tiemann L, Buck D, et al
    Prevalence of neuropathic pain in early multiple sclerosis.
    Mult Scler. 2015 Oct 19. pii: 1352458515613643.
    PubMed     Text format     Abstract available


  481. LANZILLO R, Quarantelli M, Pozzilli C, Trojano M, et al
    No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon beta1a therapy in relapsing-remitting multiple sclerosis (the ARIANNA study).
    Mult Scler. 2015 Oct 14. pii: 1352458515611222.
    PubMed     Text format     Abstract available


  482. KARAKY M, Alcina A, Fedetz M, Barrionuevo C, et al
    The multiple sclerosis-associated regulatory variant rs10877013 affects expression of CYP27B1 and VDR under inflammatory or vitamin D stimuli.
    Mult Scler. 2015 Oct 14. pii: 1352458515610208.
    PubMed     Text format     Abstract available


  483. SANDBERG L, Bistrom M, Salzer J, Vagberg M, et al
    Vitamin D and axonal injury in multiple sclerosis.
    Mult Scler. 2015 Oct 13. pii: 1352458515606986.
    PubMed     Text format     Abstract available


  484. HEDSTROM AK, Olsson T, Alfredsson L
    Smoking is a major preventable risk factor for multiple sclerosis.
    Mult Scler. 2015 Oct 12. pii: 1352458515609794.
    PubMed     Text format     Abstract available


  485. LONGBRAKE EE, Ramsbottom MJ, Cantoni C, Ghezzi L, et al
    Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.
    Mult Scler. 2015 Oct 12. pii: 1352458515608961.
    PubMed     Text format     Abstract available


  486. ZECCA C, Disanto G, Sormani MP, Riccitelli GC, et al
    Relevance of asymptomatic spinal MRI lesions in patients with multiple sclerosis.
    Mult Scler. 2015 Oct 12. pii: 1352458515599246.
    PubMed     Text format     Abstract available


  487. AKHTAR S, Alroughani R, Ahmed SF, Al-Hashel JY, et al
    Prognostic indicators of secondary progression in a paediatric-onset multiple sclerosis cohort in Kuwait.
    Mult Scler. 2015 Oct 9. pii: 1352458515608960.
    PubMed     Text format     Abstract available


  488. SIGNORIELLO E, Lanzillo R, Brescia Morra V, Di Iorio G, et al
    Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis.
    Mult Scler. 2015 Oct 9. pii: 1352458515604381.
    PubMed     Text format     Abstract available


  489. EISELE P, Konstandin S, Griebe M, Szabo K, et al
    Heterogeneity of acute multiple sclerosis lesions on sodium (23Na) MRI.
    Mult Scler. 2015 Oct 9. pii: 1352458515609430.
    PubMed     Text format     Abstract available


  490. RICCELLI R, Passamonti L, Cerasa A, Nigro S, et al
    Individual differences in depression are associated with abnormal function of the limbic system in multiple sclerosis patients.
    Mult Scler. 2015 Oct 9. pii: 1352458515606987.
    PubMed     Text format     Abstract available


  491. DEGN M, Modvig S, Dyring-Andersen B, Bonefeld CM, et al
    Increased prevalence of lymphoid tissue inducer cells in the cerebrospinal fluid of patients with early multiple sclerosis.
    Mult Scler. 2015 Oct 9. pii: 1352458515609795.
    PubMed     Text format     Abstract available


  492. STRUPP J, Voltz R, Golla H
    Opening locked doors: Integrating a palliative care approach into the management of patients with severe multiple sclerosis.
    Mult Scler. 2015 Oct 7. pii: 1352458515608262.
    PubMed     Text format     Abstract available


  493. MACDONELL R, Nagels G, Laplaud DA, Pozzilli C, et al
    Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine.
    Mult Scler. 2015 Oct 7. pii: 1352458515606809.
    PubMed     Text format     Abstract available


  494. TOBIN WO, Popescu BF, Lowe V, Pirko I, et al
    Multiple sclerosis masquerading as Alzheimer-type dementia: Clinical, radiological and pathological findings.
    Mult Scler. 2015 Oct 7. pii: 1352458515604382.
    PubMed     Text format     Abstract available


  495. HUCKE S, Wiendl H, Klotz L
    Implications of dietary salt intake for multiple sclerosis pathogenesis.
    Mult Scler. 2015 Oct 7. pii: 1352458515609431.
    PubMed     Text format     Abstract available


  496. BOVE R, Healy BC, Musallam A, Glanz BI, et al
    Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort.
    Mult Scler. 2015 Oct 7. pii: 1352458515606211.
    PubMed     Text format     Abstract available


  497. VERCELLINO M, Fenoglio C, Galimberti D, Mattioda A, et al
    Progranulin genetic polymorphisms influence progression of disability and relapse recovery in multiple sclerosis.
    Mult Scler. 2015 Oct 7. pii: 1352458515610646.
    PubMed     Text format     Abstract available


  498. YEH EA, Kinnett-Hopkins D, Grover SA, Motl RW, et al
    Physical activity and pediatric multiple sclerosis: Developing a research agenda.
    Mult Scler. 2015 Oct 7. pii: 1352458515606526.
    PubMed     Text format     Abstract available


  499. TILLEMA JM, Hulst HE, Rocca MA, Vrenken H, et al
    Regional cortical thinning in multiple sclerosis and its relation with cognitive impairment: A multicenter study.
    Mult Scler. 2015 Oct 2. pii: 1352458515607650.
    PubMed     Text format     Abstract available


  500. RATZER R, Iversen P, Bornsen L, Dyrby TB, et al
    Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis.
    Mult Scler. 2015 Oct 2. pii: 1352458515605908.
    PubMed     Text format     Abstract available


  501. ALLA S, Pearson JF, Taylor BV, Roxburgh R, et al
    An investigation of the relationship between latitude and multiple sclerosis severity in New Zealand.
    Mult Scler. 2015 Oct 2. pii: 1352458515605909.
    PubMed     Text format    


  502. DAMASCENO A, Damasceno BP, Cendes F
    No evidence of disease activity in multiple sclerosis: Implications on cognition and brain atrophy.
    Mult Scler. 2015 Oct 2. pii: 1352458515604383.
    PubMed     Text format     Abstract available


  503. KEARNEY H, Miszkiel KA, Yiannakas MC, Altmann DR, et al
    Grey matter involvement by focal cervical spinal cord lesions is associated with progressive multiple sclerosis.
    Mult Scler. 2015 Oct 2. pii: 1352458515604905.
    PubMed     Text format     Abstract available


  504. COSTA C, Martinez-Saez E, Gutierrez-Franco A, Eixarch H, et al
    Expression of semaphorin 3A, semaphorin 7A and their receptors in multiple sclerosis lesions.
    Mult Scler. 2015 Oct 2. pii: 1352458515599848.
    PubMed     Text format     Abstract available


  505. BARIZZONE N, Zara I, Sorosina M, Lupoli S, et al
    The burden of multiple sclerosis variants in continental Italians and Sardinians.
    Mult Scler. 2015;21:1385-95.
    PubMed     Text format     Abstract available


  506. HUTCHINSON M
    Multiple sclerosis relapse phenotype is an important, neglected determinant of disease-outcome: Commentary.
    Mult Scler. 2015;21:1374-5.
    PubMed     Text format    


  507. SCALFARI A
    Multiple sclerosis relapse phenotype is an important, neglected, determinant of disease outcome - NO.
    Mult Scler. 2015;21:1371-4.
    PubMed     Text format    


  508. SCOTT TF
    Multiple sclerosis relapse phenotype is an important, neglected, determinant of disease outcome - YES.
    Mult Scler. 2015;21:1369-71.
    PubMed     Text format    


    September 2015
  509. SIMULA S, Laitinen T, Laitinen TM, Tarkiainen T, et al
    Effect of fingolimod on cardiac autonomic regulation in patients with multiple sclerosis.
    Mult Scler. 2015 Sep 11. pii: 1352458515604384.
    PubMed     Text format     Abstract available


  510. GUTTMANN CR, Rousset M, Roch JA, Hannoun S, et al
    Multiple sclerosis lesion formation and early evolution revisited: A weekly high-resolution magnetic resonance imaging study.
    Mult Scler. 2015 Sep 11. pii: 1352458515600247.
    PubMed     Text format     Abstract available


  511. KUHLE J, Hardmeier M, Disanto G, Gugleta K, et al
    A 10-year follow-up of the European multicenter trial of interferon beta-1b in secondary-progressive multiple sclerosis.
    Mult Scler. 2015 Sep 11. pii: 1352458515594440.
    PubMed     Text format     Abstract available


  512. MARTINEZ-RODRIGUEZ JE, Cobo-Calvo A, Villar LM, Munteis E, et al
    Adaptive natural killer cell response to cytomegalovirus and disability progression in multiple sclerosis.
    Mult Scler. 2015 Sep 11. pii: 1352458515601215.
    PubMed     Text format     Abstract available


  513. MOCCIA M, Lanzillo R, Palladino R, Chang KC, et al
    Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression.
    Mult Scler. 2015 Sep 11. pii: 1352458515599075.
    PubMed     Text format     Abstract available


  514. UHER T, Horakova D, Tyblova M, Zeman D, et al
    Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later.
    Mult Scler. 2015 Sep 11. pii: 1352458515601903.
    PubMed     Text format     Abstract available


  515. SEPULVEDA M, Ros C, Martinez-Lapiscina EH, Sola-Valls N, et al
    Pituitary-ovary axis and ovarian reserve in fertile women with multiple sclerosis: A pilot study.
    Mult Scler. 2015 Sep 11. pii: 1352458515602339.
    PubMed     Text format     Abstract available


  516. BINZER S, Stenager E, Binzer M, Kyvik KO, et al
    Genetic analysis of the isolated Faroe Islands reveals SORCS3 as a potential multiple sclerosis risk gene.
    Mult Scler. 2015 Sep 11. pii: 1352458515602338.
    PubMed     Text format     Abstract available


  517. BAKSHI R, Haring DA
    Comment on "Fingolimod effects on left ventricular function in multiple sclerosis" Mult Scler 2015.
    Mult Scler. 2015 Sep 10. pii: 1352458515600250.
    PubMed     Text format    


    August 2015
  518. ROCCA MA, Morelli ME, Amato MP, Moiola L, et al
    Regional hippocampal involvement and cognitive impairment in pediatric multiple sclerosis.
    Mult Scler. 2015 Aug 18. pii: 1352458515598569.
    PubMed     Text format     Abstract available


  519. PLEMEL JR, Juzwik CA, Benson CA, Monks M, et al
    Over-the-counter anti-oxidant therapies for use in multiple sclerosis: A systematic review.
    Mult Scler. 2015 Aug 18. pii: 1352458515601513.
    PubMed     Text format     Abstract available


  520. GONSETTE R, Debouverie M, Sindic C, Ferre JC, et al
    Pixantrone: a B-cell-depleting immunosuppressant for multiple sclerosis patients with active disease.
    Mult Scler. 2015 Aug 18. pii: 1352458515601902.
    PubMed     Text format     Abstract available


  521. BHARGAVA P, Steele SU, Waubant E, Revirajan NR, et al
    Multiple sclerosis patients have a diminished serologic response to vitamin D supplementation compared to healthy controls.
    Mult Scler. 2015 Aug 18. pii: 1352458515600248.
    PubMed     Text format     Abstract available


  522. KRAEMER M, Weber R, Herold M, Berlit P, et al
    Reversible cerebral vasoconstriction syndrome associated with fingolimod treatment in relapsing-remitting multiple sclerosis three months after childbirth.
    Mult Scler. 2015 Aug 17. pii: 1352458515600249.
    PubMed     Text format     Abstract available


  523. TACCONI P, Peltz MT, Lorefice L, Marrosu MG, et al
    Facial synkinesis as a first symptom of multiple sclerosis.
    Mult Scler. 2015 Aug 5. pii: 1352458515584415.
    PubMed     Text format     Abstract available


  524. MCKAY KA, Tremlett H, Fisk JD, Patten SB, et al
    Adverse health behaviours are associated with depression and anxiety in multiple sclerosis: A prospective multisite study.
    Mult Scler. 2015 Aug 5. pii: 1352458515599073.
    PubMed     Text format     Abstract available


  525. HUTCHINSON M
    The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level: Commentary.
    Mult Scler. 2015 Aug 4. pii: 1352458515599682.
    PubMed     Text format    


  526. ARRAMBIDE G, Espejo C, Tintore M
    The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level-NO.
    Mult Scler. 2015 Aug 4. pii: 1352458515589774.
    PubMed     Text format    


  527. MILLER DM, Bethoux F, Victorson D, Nowinski CJ, et al
    Validating Neuro-QoL short forms and targeted scales with people who have multiple sclerosis.
    Mult Scler. 2015 Aug 3. pii: 1352458515599450.
    PubMed     Text format     Abstract available


  528. FISHER E, Nakamura K, Lee JC, You X, et al
    Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: A retrospective analysis.
    Mult Scler. 2015 Aug 3. pii: 1352458515599072.
    PubMed     Text format     Abstract available


  529. COHEN M, Lebrun C, Ayrignac X, Labauge P, et al
    Solitary sclerosis: Experience from three French tertiary care centres.
    Mult Scler. 2015;21:1216.
    PubMed     Text format    


    July 2015
  530. CHILCOT J, Norton S, Kelly ME, Moss-Morris R, et al
    The Chalder Fatigue Questionnaire is a valid and reliable measure of perceived fatigue severity in multiple sclerosis.
    Mult Scler. 2015 Jul 31. pii: 1352458515598019.
    PubMed     Text format     Abstract available


  531. ROY S, Rodgers J, Drake AS, Zivadinov R, et al
    Stable neuropsychiatric status in multiple sclerosis: a 3-year study.
    Mult Scler. 2015 Jul 30. pii: 1352458515597570.
    PubMed     Text format     Abstract available


  532. SAMARAWEERA AP, Cohen SN, Akay EM, Evangelou N, et al
    Lymphomatoid papulosis: A cutaneous lymphoproliferative disorder in a patient on fingolimod for multiple sclerosis.
    Mult Scler. 2015 Jul 28. pii: 1352458515597568.
    PubMed     Text format     Abstract available


  533. DAAMS M, Steenwijk MD, Schoonheim MM, Wattjes MP, et al
    Multi-parametric structural magnetic resonance imaging in relation to cognitive dysfunction in long-standing multiple sclerosis.
    Mult Scler. 2015 Jul 24. pii: 1352458515596598.
    PubMed     Text format     Abstract available


  534. DULA AN, Pawate S, Dortch RD, Barry RL, et al
    Magnetic resonance imaging of the cervical spinal cord in multiple sclerosis at 7T.
    Mult Scler. 2015 Jul 24. pii: 1352458515591070.
    PubMed     Text format     Abstract available


  535. WEIER K, Till C, Fonov V, Yeh EA, et al
    Contribution of the cerebellum to cognitive performance in children and adolescents with multiple sclerosis.
    Mult Scler. 2015 Jul 22. pii: 1352458515595132.
    PubMed     Text format     Abstract available


  536. ROCCA MA, Sonkin M, Copetti M, Pagani E, et al
    Diffusion tensor magnetic resonance imaging in very early onset pediatric multiple sclerosis.
    Mult Scler. 2015 Jul 21. pii: 1352458515596600.
    PubMed     Text format     Abstract available


  537. GERSCHENFELD G, Servy A, Valeyrie-Allanore L, de Prost N, et al
    Fatal toxic epidermal necrolysis in a patient on teriflunomide treatment for relapsing multiple sclerosis.
    Mult Scler. 2015 Jul 21. pii: 1352458515596601.
    PubMed     Text format     Abstract available


  538. HILVEN K, Goris A
    Genetic burden mirrors epidemiology of multiple sclerosis.
    Mult Scler. 2015 Jul 21. pii: 1352458515596603.
    PubMed     Text format    


  539. VAN DER MEI I, Lucas RM, Taylor BV, Valery PC, et al
    Population attributable fractions and joint effects of key risk factors for multiple sclerosis.
    Mult Scler. 2015 Jul 21. pii: 1352458515594040.
    PubMed     Text format     Abstract available


  540. PRESSLAUER S, Milosavljevic D, Huebl W, Aboulenein-Djamshidian F, et al
    Validation of kappa free light chains as a diagnostic biomarker in multiple sclerosis and clinically isolated syndrome: A multicenter study.
    Mult Scler. 2015 Jul 21. pii: 1352458515594044.
    PubMed     Text format     Abstract available


  541. WARRENDER-SPARKES M, Spelman T, Izquierdo G, Trojano M, et al
    The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.
    Mult Scler. 2015 Jul 21. pii: 1352458515594041.
    PubMed     Text format     Abstract available


  542. NUNAN-SAAH J, Paulraj SR, Waubant E, Krupp LB, et al
    Neuropsychological correlates of multiple sclerosis across the lifespan.
    Mult Scler. 2015 Jul 10. pii: 1352458515586088.
    PubMed     Text format     Abstract available


  543. PICHLER A, Khalil M, Langkammer C, Pinter D, et al
    Combined analysis of global and compartmental brain volume changes in early multiple sclerosis in clinical practice.
    Mult Scler. 2015 Jul 10. pii: 1352458515593405.
    PubMed     Text format     Abstract available


  544. GOVEROVER Y, Chiaravalloti N, DeLuca J
    Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) and performance of everyday life tasks: Actual Reality.
    Mult Scler. 2015 Jul 10. pii: 1352458515593637.
    PubMed     Text format     Abstract available


  545. FAVARETTO A, Lazzarotto A, Poggiali D, Rolma G, et al
    MRI-detectable cortical lesions in the cerebellum and their clinical relevance in multiple sclerosis.
    Mult Scler. 2015 Jul 10. pii: 1352458515594043.
    PubMed     Text format     Abstract available


  546. CIRILLO S, Rocca MA, Ghezzi A, Valsasina P, et al
    Abnormal cerebellar functional MRI connectivity in patients with paediatric multiple sclerosis.
    Mult Scler. 2015 Jul 10. pii: 1352458515592191.
    PubMed     Text format     Abstract available


  547. RAMANATHAN S, Prelog K, Barnes EH, Tantsis EM, et al
    Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis.
    Mult Scler. 2015 Jul 10. pii: 1352458515593406.
    PubMed     Text format     Abstract available


  548. ZARBO IR, Minacapelli E, Falautano M, Demontis S, et al
    Personality traits predict perceived health-related quality of life in persons with multiple sclerosis.
    Mult Scler. 2015 Jul 10. pii: 1352458515594045.
    PubMed     Text format     Abstract available


    June 2015
  549. 'T HART BA
    Why does multiple sclerosis only affect human primates?
    Mult Scler. 2015 Jun 25. pii: 1352458515591862.
    PubMed     Text format     Abstract available


  550. RAMO-TELLO C, Tintore M, Rovira A, Ramio-Torrenta L, et al
    Baseline clinical status as a predictor of methylprednisolone response in multiple sclerosis relapses.
    Mult Scler. 2015 Jun 25. pii: 1352458515590648.
    PubMed     Text format     Abstract available


  551. HERTWIG L, Pache F, Romero-Suarez S, Sturner KH, et al
    Distinct functionality of neutrophils in multiple sclerosis and neuromyelitis optica.
    Mult Scler. 2015 Jun 25. pii: 1352458515586084.
    PubMed     Text format     Abstract available


  552. KOENIG KA, Sakaie KE, Lowe MJ, Lin J, et al
    The relationship between cognitive function and high-resolution diffusion tensor MRI of the cingulum bundle in multiple sclerosis.
    Mult Scler. 2015 Jun 23. pii: 1352458515576983.
    PubMed     Text format     Abstract available


  553. FAINARDI E, Bortolotti D, Bolzani S, Castellazzi M, et al
    Cerebrospinal fluid amounts of HLA-G in dimeric form are strongly associated to patients with MRI inactive multiple sclerosis.
    Mult Scler. 2015 Jun 17. pii: 1352458515590647.
    PubMed     Text format     Abstract available


  554. HUGHES SE, Gray OM
    Symptomatic therapy in multiple sclerosis: Big pharma should do more - NO.
    Mult Scler. 2015 Jun 17. pii: 1352458515587930.
    PubMed     Text format    


  555. SIVA A, Kantarci O
    Symptomatic therapy in multiple sclerosis: Big pharma should do more-YES.
    Mult Scler. 2015 Jun 17. pii: 1352458515588974.
    PubMed     Text format    


  556. HUTCHINSON M
    Symptomatic therapy in multiple sclerosis: Big pharma should do more - commentary.
    Mult Scler. 2015 Jun 17. pii: 1352458515590281.
    PubMed     Text format    


  557. HOANG H, Laursen B, Stenager EN, Stenager E, et al
    Psychiatric co-morbidity in multiple sclerosis: The risk of depression and anxiety before and after MS diagnosis.
    Mult Scler. 2015 Jun 3. pii: 1352458515588973.
    PubMed     Text format     Abstract available


  558. BARUCH NF, O'Donnell EH, Glanz BI, Benedict RH, et al
    Cognitive and patient-reported outcomes in adults with pediatric-onset multiple sclerosis.
    Mult Scler. 2015 Jun 3. pii: 1352458515588781.
    PubMed     Text format     Abstract available


  559. SBARDELLA E, Tona F, Petsas N, Upadhyay N, et al
    Functional connectivity changes and their relationship with clinical disability and white matter integrity in patients with relapsing-remitting multiple sclerosis.
    Mult Scler. 2015 Jun 3. pii: 1352458514568826.
    PubMed     Text format     Abstract available


  560. THEAUDIN M, Romero K, Feinstein A
    In multiple sclerosis anxiety, not depression, is related to gender.
    Mult Scler. 2015 Jun 3. pii: 1352458515588582.
    PubMed     Text format     Abstract available


  561. VAN NIEROP GP, Mautner J, Mitterreiter JG, Hintzen RQ, et al
    Intrathecal CD8 T-cells of multiple sclerosis patients recognize lytic Epstein-Barr virus proteins.
    Mult Scler. 2015 Jun 3. pii: 1352458515588581.
    PubMed     Text format     Abstract available


  562. CICCARELLI O, Toosy AT
    Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study.
    Mult Scler. 2015 Jun 3. pii: 1352458515588583.
    PubMed     Text format    


  563. RACCA V, Di Rienzo M, Cavarretta R, Toccafondi A, et al
    Fingolimod effects on left ventricular function in multiple sclerosis.
    Mult Scler. 2015 Jun 3. pii: 1352458515587753.
    PubMed     Text format     Abstract available


    May 2015
  564. YALDIZLI O, Pardini M, Sethi V, Muhlert N, et al
    Characteristics of lesional and extra-lesional cortical grey matter in relapsing-remitting and secondary progressive multiple sclerosis: A magnetisation transfer and diffusion tensor imaging study.
    Mult Scler. 2015 May 26. pii: 1352458515586085.
    PubMed     Text format     Abstract available


  565. HEINE M, Wens I, Langeskov-Christensen M, Verschuren O, et al
    Cardiopulmonary fitness is related to disease severity in multiple sclerosis.
    Mult Scler. 2015 May 26. pii: 1352458515581437.
    PubMed     Text format     Abstract available


  566. RAMANATHAN S, Sato S, Matsushita T, Masaki K, et al
    Antibodies to myelin oligodendrocyte glycoprotein are uncommon in Japanese opticospinal multiple sclerosis.
    Mult Scler. 2015 May 26. pii: 1352458515586089.
    PubMed     Text format    


  567. BJORNEVIK K, Riise T, Cortese M, Holmoy T, et al
    Level of education and multiple sclerosis risk after adjustment for known risk factors: The EnvIMS study.
    Mult Scler. 2015 May 26. pii: 1352458515579444.
    PubMed     Text format     Abstract available


  568. MACMILLAN EL, Tam R, Zhao Y, Vavasour IM, et al
    Progressive multiple sclerosis exhibits decreasing glutamate and glutamine over two years.
    Mult Scler. 2015 May 26. pii: 1352458515586086.
    PubMed     Text format     Abstract available


  569. DEASON K, Miller-Little WA, Stuve O
    Natalizumab and monocytes in multiple sclerosis: The dim haze of mystery and the enchantment of pursuit.
    Mult Scler. 2015 May 26. pii: 1352458515574150.
    PubMed     Text format    


  570. VAN DER WALT A, Buzzard K, Sung S, Spelman T, et al
    The occurrence of dystonia in upper-limb multiple sclerosis tremor.
    Mult Scler. 2015 May 26. pii: 1352458515577690.
    PubMed     Text format     Abstract available


  571. MATTIOLI F, Bellomi F, Stampatori C, Capra R, et al
    Neuroenhancement through cognitive training and anodal tDCS in multiple sclerosis.
    Mult Scler. 2015 May 26. pii: 1352458515587597.
    PubMed     Text format     Abstract available


  572. LONGBRAKE EE, Cross AH
    Dimethyl fumarate associated lymphopenia in clinical practice.
    Mult Scler. 2015;21:796-7.
    PubMed     Text format    


  573. SASTRE-GARRIGA J, Tur C, Pareto D, Vidal-Jordana A, et al
    Brain atrophy in natalizumab-treated patients: A 3-year follow-up.
    Mult Scler. 2015;21:749-56.
    PubMed     Text format     Abstract available


  574. VIDAL-JORDANA A, Tintore M, Tur C, Perez-Miralles F, et al
    Significant clinical worsening after natalizumab withdrawal: Predictive factors.
    Mult Scler. 2015;21:780-5.
    PubMed     Text format     Abstract available


  575. COMI G, Gold R, Dahlke F, Sinha A, et al
    Relapses in patients treated with fingolimod after previous exposure to natalizumab.
    Mult Scler. 2015;21:786-90.
    PubMed     Text format     Abstract available


    April 2015
  576. SINDIC C, Edan G
    Richard E Gonsette (1929-2014).
    Mult Scler. 2015;21:540.
    PubMed     Text format    


  577. PEAUREAUX D, Pignolet B, Biotti D, Bucciarelli F, et al
    Fingolimod treatment after natalizumab-related progressive multifocal leukoencephalopathy: three new cases.
    Mult Scler. 2015;21:671-2.
    PubMed     Text format    


  578. PESCHL P, Reindl M, Schanda K, Sospedra M, et al
    Antibody responses following induction of antigen-specific tolerance with antigen-coupled cells.
    Mult Scler. 2015;21:651-5.
    PubMed     Text format     Abstract available


  579. ELLIS R, Brown S, Boggild M
    Therapy-related acute leukaemia with mitoxantrone: four years on, what is the risk and can it be limited?
    Mult Scler. 2015;21:642-5.
    PubMed     Text format     Abstract available


  580. HANKEN K, Eling P, Hildebrandt H
    Is there a cognitive signature for MS-related fatigue?
    Mult Scler. 2015;21:376-81.
    PubMed     Text format     Abstract available


    January 2015
  581. HAUSER SL
    The Charcot Lecture | beating MS: a story of B cells, with twists and turns.
    Mult Scler. 2015;21:8-21.
    PubMed     Text format     Abstract available


  582. VAN SCHEPENDOM J, D'hooghe MB, Cleynhens K, D'hooge M, et al
    Reduced information processing speed as primum movens for cognitive decline in MS.
    Mult Scler. 2015;21:83-91.
    PubMed     Text format     Abstract available


  583. NILSAGARD Y, Gunn H, Freeman J, Hoang P, et al
    Falls in people with MS--an individual data meta-analysis from studies from Australia, Sweden, United Kingdom and the United States.
    Mult Scler. 2015;21:92-100.
    PubMed     Text format     Abstract available


    October 2014
  584. ALROUGHANI R
    High discontinuation rate of natalizumab in JC virus seropositive patients due to significant anxiety and safety feelings.
    Mult Scler. 2014;20:1667-8.
    PubMed     Text format    


    August 2014
  585. VAN ROSSUM JA, Vennegoor A, Killestein J
    The effect of prolonged natalizumab treatment on anxiety and safety in JC virus-seropositive MS patients; a follow-up study.
    Mult Scler. 2014 Aug 11. pii: 1352458514543341.
    PubMed     Text format    


    July 2014
  586. VENNEGOOR A, Rispens T, Van Oosten B, Wattjes M, et al
    Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.
    Mult Scler. 2014 Jul 30. pii: 1352458514541507.
    PubMed     Text format     Abstract available


    May 2014
  587. MATELL H, Lycke J, Svenningsson A, Holmen C, et al
    Age-dependent effects on the treatment response of natalizumab in MS patients.
    Mult Scler. 2014 May 27. pii: 1352458514536085.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: